

Mammalian epoxide hydrolases in xenobiotic metabolism and signalling

Martina Decker · Michael Arand · Annette Cronin

Received: 11 February 2009 / Accepted: 16 February 2009 / Published online: 2 April 2009
© Springer-Verlag 2009

Abstract Epoxide hydrolases catalyse the hydrolysis of electrophilic—and therefore potentially genotoxic—epoxides to the corresponding less reactive vicinal diols, which explains the classification of epoxide hydrolases as typical detoxifying enzymes. The best example is mammalian microsomal epoxide hydrolase (mEH)—an enzyme prone to detoxification—due to a high expression level in the liver, a broad substrate selectivity, as well as inducibility by foreign compounds. The mEH is capable of inactivating a large number of structurally different, highly reactive epoxides and hence is an important part of the enzymatic defence of our organism against adverse effects of foreign compounds. Furthermore, evidence is accumulating that mammalian epoxide hydrolases play physiological roles other than detoxification, particularly through involvement in signalling processes. This certainly holds true for soluble epoxide hydrolase (sEH) whose main function seems to be the turnover of lipid derived epoxides, which are signalling lipids with diverse functions in regulatory processes, such as control of blood pressure, inflammatory processes, cell proliferation and nociception. In recent years, the sEH has attracted attention as a promising target for pharmacological inhibition to treat hypertension and possibly other diseases. Recently, new hitherto uncharacterised epoxide hydrolases could be identified in mammals by genome analysis. The expression pattern and substrate selectivity of these new epoxide hydrolases suggests their participation in signalling processes rather than a role in detoxification. Taken together, epoxide hydrolases (1) play a central role

in the detoxification of genotoxic epoxides and (2) have an important function in the regulation of physiological processes by the control of signalling molecules with an epoxide structure.

Keywords Epoxide hydrolase · Xenobiotic metabolism · EPHX · ABHD · Lipid signalling · peg1/MEST · EET · Cholesterol · Lipid phosphatase

Introduction

Epoxide hydrolases (EC 3.3.2.7-11) catalyse the hydrolysis of epoxides to the corresponding vicinal diols by the addition of water. Xenobiotic derived epoxides can be formed within the body as reactive intermediates during metabolic processes by monooxygenation of carbon double bonds in olefines or aromatic ring systems. Based on the ring tension of such cyclic compounds in combination with a polarisation of the CO bond, epoxides often show electrophilic reactivity leading to a certain genotoxic potential (Fig. 1a). Two mammalian enzymes—microsomal (mEH) and soluble epoxide hydrolase (sEH)—that classically play a major role in xenobiotic metabolism have been intensely characterised. Apart from a few exceptions the hydrolysis of an epoxide results in an increased water solubility of the metabolites and the termination of its genotoxic potential. Therefore mammalian epoxide hydrolases, in particular the mEH with its exceptionally broad substrate selectivity against a diverse group of epoxides, perfectly serve their function as xenobiotic metabolising enzymes (Fig. 1b).

This picture, however, needs some adjustment. It is now well established that the organism utilises a large number of endogenous epoxides—in particular epoxides derived from unsaturated fatty acids, such as epoxyeicosatrienoic acid

M. Decker · M. Arand · A. Cronin (✉)
Institute of Pharmacology and Toxicology,
University of Zürich, Winterthurer Str. 190,
8057 Zurich, Switzerland
e-mail: cronin@pharma.uzh.ch




Fig. 1 The role of epoxide hydrolase in xenobiotic metabolism and cell signalling. **a** Epoxides are in general chemically reactive compounds, due to the electronegativity of the ring oxygen in combination with a certain ring tension. **b** Reactive epoxides may be taken up by the body as xenobiotic substrates or formed during metabolism, mainly by the action of cytochrome P450 dependant monooxygenases. On the other hand, many epoxides without any genotoxic potential have been identified as endogenous signalling molecules, which display numerous functions within the organism. The turnover of epoxide to the corresponding diols by epoxide hydrolases is most often considered a detoxifying reaction. Rather rare exceptions where (1) the action of an EH leads to metabolic bioactivation, or (2) the diol reaction product still has signalling function are outlined in the respective chapters in the text

(EETs) and leukotriene A_4 (LTA_4)—as signalling molecules. Due to their low chemical reactivity, these epoxides have little genotoxic potential, but instead serve as important signalling molecules, regulating a large variety of physiological functions, ranging from the regulation of vascular tone, to inflammation, angiogenesis and pain. Human sEH, which is highly expressed throughout the body, is to date regarded as the primary enzyme in the metabolism of such endogenous epoxides (Fig. 1b). Our recently discovered phosphatase activity of human sEH further highlights the role of this enzyme in regulatory processes rather than xenobiotic metabolism. Yet, it also serves a complementary function to mEH in xenobiotic metabolism due to the acceptance of certain *trans*-substituted epoxides.

Apart from the two well analysed EHs additional mammalian epoxide hydrolases contribute to the metabolism of epoxides. Both sEH and mEH show an overall low sequence homology but both belong to the family of α/β hydrolase fold enzymes, based on structural similarities. Using common structural elements of the α/β hydrolase fold, candidate enzymes from the mammalian genomes may be identified representing potential epoxide hydrolases. Our group has recently cloned and expressed two such genes that we name epoxide hydrolase 3 (EH3) and 4 (EH4) (manuscript in preparation) from the human genome. Furthermore, the product of the *peg1/MEST* gene was already in 1995 predicted to represent an α/β hydrolase fold epoxide hydrolase (Kaneko-Ishino et al. 1995). The physio-

logical functions of these novel (potential) epoxide hydrolases in xenobiotic metabolism and/or lipid signalling still needs to be determined.

Additional epoxide hydrolases with narrow substrate selectivity—and therefore an unlikely role in xenobiotic metabolism—have been characterised in mammals, based on their enzymatic functions. Of those, mammalian leukotriene A_4 hydrolase (LTA_4H), which is involved in the turnover of the lipid mediator LTA_4 to LTB_4 , is best characterised (Haeggstrom 2004). LTA_4 hydrolase does not belong to the α/β hydrolase fold enzyme family but instead represents a zinc dependant metalloprotease, which—as an exception compared to all other EHs—forms a non-vicinal diol from its substrate. Less well-investigated are Hepoxilin A_3 epoxide hydrolase and cholesterol epoxide hydrolase (ChEH) which were identified as the main hydrolase of the endogenous lipids hepoxilin A_3 (Pace-Asciak and Lee 1989) and cholesterol-5,6-epoxide (Watabe et al. 1986), respectively. To date, both enzymes are still only incompletely characterised and no sequence or structural information is available.

Most known epoxide hydrolases belong to the large family of α/β hydrolase fold enzymes and are found in nearly every organism (van Loo et al. 2006). Yet, in bacteria also different strategies for epoxide hydrolysis evolved. Such enzymes are generally specialised on a function in one specific pathway rather than accepting a broad spectrum of substrates. The limonene epoxide hydrolase (LEH) from *Rhodococcus erythropolis* (van der Werf et al. 1998), as well as a homologous EH (TbEH1) from *Mycobacterium tuberculosis* represent enzymes smaller than the general α/β hydrolase fold EHs, and utilise a single step mechanism for epoxide hydrolysis. A distinct class of EHs is represented by the FosX epoxide hydrolases from microorganisms such as *Mesorhizobium loti* and *Listeria monocytogenes* which selectively hydrolyses the antibiotic Fosfomycin by a mechanism including the direct addition of water (Fillgrove et al. 2003; Rigsby et al. 2005).

This review focuses on an update of the α/β hydrolase fold family of mammalian epoxide hydrolases and their role in xenobiotic metabolism, but will also summarise the functions of these enzymes which derive from hydrolysis of endogenous lipid mediators.

Nomenclature of epoxide hydrolases

Several epoxide hydrolases and their corresponding genes have been characterised in mammals. Historically, these enzymes were named after the species of origin, the subcellular localisation and/or their substrate specificity. Given that the present gene nomenclature is not consistent but most of the mammalian EHs belong to the α/β hydrolase

fold family of enzymes, a more systematic nomenclature based on evolutionary relation similar to the cytochrome P450 monooxygenases (CYP) nomenclature seems appropriate. The two well investigated mammalian EHs have been named EPHX1 (mEH) and EPHX2 (sEH) by the HUGO gene nomenclature committee, therefore we suggest that this nomenclature should also be used for new members of the α/β hydrolase fold EH enzyme family (Table 1). As mentioned earlier, we identified two new epoxide hydrolase genes (presently termed ABHD7 and ABHD9 based on a predicted α/β hydrolase fold) with 45% sequence identity in the mammalian genome (Fig. 2), at least one of which acts as an epoxide hydrolase on lipid derived epoxides (manuscript in preparation). Two structurally very closely related EHs from *Caenorhabditis elegans* have very recently been described (Harris et al. 2008) as active epoxide hydrolases. Therefore we suggest terming the two new mammalian enzymes EH3 and EH4 and propose changing their gene names into EPHX3 and EPHX4. Because for the *peg1/MEST* gene product the evidence for epoxide hydrolase activity has not been proven so far, and for ChEH and Hepoxilin A₃ hydrolase no sequence information is available yet, we propose terming the next sequence- and substrate-characterised α/β hydrolase fold epoxide hydrolase EH5.

Gene evolution and structure of α/β hydrolase fold epoxide hydrolases

The α/β hydrolase fold family comprises of a broad variety of enzymes with catalytic activities ranging from esterases

Table 1 Nomenclature of mammalian α/β hydrolase fold epoxide hydrolases

Gene description present	Recommended	Protein description recommended
EPHX1 (HYL1)	EPHX1	Microsomal epoxide hydrolase, mEH
EPHX2 (HYL2)	EPHX2	Soluble epoxide hydrolase, sEH
ABHD9	EPHX3	Epoxide hydrolase 3, EH3
ABHD7	EPHX4	Epoxide hydrolase 4, EH4
<i>Peg1/MEST</i>	(EPHX5, possibly)	MEST

Peg1/MEST should only be termed EPHX5 when the MEST protein has confirmed epoxide hydrolase activity. We do not recommend involving non- α/β hydrolase fold EHs, e.g. Leukotriene A₄ hydrolase (LTA₄H), or other mammalian EHs like Hepoxilin A₃ hydrolase and Cholesterol epoxide hydrolase (ChEH) in the respective nomenclature, unless sequence information is available

EPHX Epoxide hydrolase xenobiotic, *HYL* hydrolase, *ABHD* α/β hydrolase, *Peg1/MEST* paternally expressed gene 1/mesoderm specific transcript




Fig. 2 Phylogenetic tree of mammalian epoxide hydrolases. Protein sequence comparison of human epoxide hydrolases sEH, mEH, EH3, EH4 as well as MEST in their α/β hydrolase fold domains (displayed in red). The percent sequence identity is indicated at the branches. The lid domains are coloured in green. All proteins contain variable N-terminal extension, such as the phosphatase domain (blue) in case of the soluble epoxide hydrolase, membrane anchors (grey) or the N-terminal meander of microsomal epoxide hydrolase (yellow)


(acetylcholinesterase being the most prominent) to epoxide hydrolases, haloalkane dehalogenases and lipases (Holmquist 2000). The sequence similarity of the first cloned epoxide hydrolase—mEH (Gonzalez and Kasper 1981)—and the first described bacterial haloalkane dehalogenase (Janssen et al. 1989) is minimal but a classification into the α/β hydrolase fold family of enzymes based on structural similarities (Arand et al. 1994; Lacourciere and Armstrong 1994; Beetham et al. 1995) was suggested after (1) cloning of the related sEH (Beetham et al. 1993; Grant et al. 1993; Knehr et al. 1993), and (2) determination of the crystal structure of haloalkane dehalogenase (Franken et al. 1991). The structural relationship of epoxide hydrolases has been described in detail in a recent review (Arand et al. 2003a). Since then approximately 240 epoxide hydrolase genes have been described from plants, fungi, insects and bacteria (Beetham et al. 1993, 1995; Smit 2004; van Loo et al. 2006). Another recent excellent review describes the genome wide analysis for epoxide hydrolases and evolutionary relationship of the identified enzymes with an average amino acid sequence identity of 14% into eight phylogenetically related groups (van Loo et al. 2006).

The first structure of an EH from *Agrobacterium radiobacter* (Nardini et al. 1999) with sequence similarity to mammalian sEH revealed typical structural elements of α/β hydrolase fold EHs. Common to all is a conserved fold consisting of an arrangement of eight central β -strands, flanked by several α -helices. A variable lid domain that is inserted between strand 6 and 7 covers this α/β hydrolase core fold (Holmquist 2000). Both, core and lid domains constitute the epoxide hydrolase substrate binding pocket at the interaction site. Similar in all family members is a catalytic triad formed by the central fold consisting of an Asp-His-Asp/Glu motif (catalytic nucleophile—water activating histidine—acidic residue, forming a charge relay system with

the histidine), located on top of certain loops (Fig. 3). In the primary sequence the order of the catalytic triad is nucleophile-acid-histidine (Arand et al. 1994). The lid domain presents two tyrosine residues which position the epoxide within the active site. These two tyrosines distinguish epoxide hydrolases from other members of the α/β hydrolase fold family. The latter fold is ideally suited to a detoxifying enzyme that needs to be able to turn over a large number of structurally diverse epoxides (Arand et al. 2003a), because the catalytic nucleophile is positioned at the top of a flexible turn and therefore able to accept structurally diverse epoxides. A negative charge which is formed on the carbonyl oxygen of the catalytic nucleophile (see mechanism

below) is stabilised further by a backbone amide of a conserved sequence stretch HGXP (where X is usually aromatic) called oxyanion hole. Apart from these motifs, the overall sequence variation is high which is typical for this type of enzymes (a comparison of the EHs from *A. radiobacter* and *A. niger* shows little sequence similarity but the backbones of their α/β hydrolase fold domains are nearly perfectly superimposable). To date the structures of several α/β hydrolase fold epoxide hydrolases, in particular of murine (Argiriadi et al. 1999) and human (Gomez et al. 2004) sEH, but also of plant (Mowbray et al. 2006), fungal (Zou et al. 2000) and bacterial enzymes (Nardini et al. 1999) have been solved.

Fig. 3 Three dimensional structure and enzymatic mechanism of α/β hydrolase fold EHs. The structure model represents the *Aspergillus niger* epoxide hydrolase, a close relative of the mammalian mEH, prepared using the program PyMOL (v9.07; DeLano Scientific LLC, San Carlos, CA, USA) based on the coordinates from PDB data file 1QO7. **a** Complete subunit with the α/β hydrolase fold displayed in red, the lid domain in green and the N-terminal meander in gold. **b** Stereo view of the mEH active site, showing the residues relevant for catalysis. **c** Two step catalytic mechanism of epoxide hydrolysis as described in detail in the text



The N-terminal domain varies among mammalian epoxide hydrolases (Arand et al. 2003a) (Fig. 2). While the α/β hydrolase fold in mEH and most likely EH3 and 4 is preceded by a membrane anchor, the N-terminal domain of mammalian sEH acts as a phosphatase and structurally belongs to a distinct class of haloacid dehalogenases (HAD). Structure and function of this additional domain is detailed in the respective sEH chapter below.

Catalytic mechanism of epoxide hydrolysis

Much work has been invested in elucidating the catalytic mechanism of epoxide hydrolases (Arand et al. 1996; Muller et al. 1997; Laughlin et al. 1998; Argiriadi et al. 1999; Armstrong and Cassidy 2000; Zou et al. 2000; Arand et al. 2003c; Elfstrom and Widersten 2006) which is well understood by now. The overall reaction catalyses the addition of water to the oxirane ring leading to a vicinal diol as reaction product, including the formation of an ester intermediate as outlined in Fig. 3c. As described above the active site is composed of a catalytic triad build from the active site residues aspartic acid (catalytic nucleophile), histidine (general base) and aspartic or glutamic acid (charge relay acid). The catalytic triad is supported in catalysis by the two tyrosine residues coming from the lid. The hydroxy groups of these tyrosines hydrogen bond to the epoxide oxygen, once the substrate has entered the active site, and thereby position and activate the epoxide for the catalytic reaction. In the first chemical reaction step the catalytic nucleophile attacks the oxirane ring (with certain stereo- and enantioselectivity depending on the enzyme) at one of the two carbon atoms to form a covalent intermediate (Lacourciere et al. 1993). In a second step the enzyme substrate ester intermediate is then hydrolysed by a water molecule, which is activated by proton abstraction from the histidine of the catalytic triad. The resulting positive charge is shielded by the acidic amino acid residue, either a glutamic (in mammalian EHs) or aspartic acid (in most other EHs) and the oxyanion hole stabilises the intermediate state. The catalytic nucleophile is located on a nucleophilic elbow, and can therefore adapt to the position of the substrate epoxide with some flexibility. This setting represents the ideal active site for broad substrate specificity.

Such a mechanism has some important implications in the detoxification capacity of epoxide hydrolases (Arand et al. 2003c). The rate limiting step of the overall reaction is the hydrolysis of the ester intermediate (Laughlin et al. 1998; Arand et al. 1999a) and release of a diol product. However, in the first reaction step—which represents substrate consumption—the mEH is efficiently able to detoxify

a variety of substrates, although with low V_{max} .¹ The latter fact is accomplished by the fortunate high expression level of mEH in the liver and a generally low concentration of epoxide substrates. Nonetheless, if the formation rate of a reactive epoxide intermediate exceeds the elimination capacity of the mEH, its steady state level is escaping the control of the enzyme. This may represent the mechanistic basis of a practical threshold for chemical carcinogenesis by compounds that are detoxified by mEH (Oesch et al. 2000).

The catalytic addition of water to oxiranes by α/β hydrolase fold epoxide hydrolases as described above is not the only possible mechanism to metabolise epoxides. To make matters complete, three other mechanisms for epoxide hydrolysis have evolved. Mammalian LTA₄ hydrolase (Haeggstrom et al. 2002) as well as the FosX epoxide hydrolases from *Mesorhizobium loti* (Fillgrove et al. 2003; Rigsby et al. 2005) are both metalloenzymes that activate the oxirane by coordination with Zn²⁺ and Mn²⁺, respectively. While FosX hydrolyses its substrate by direct addition of water, LTA₄ introduces the water three double bonds afar from the epoxide, resulting—as an exception—in a non-vicinal diol. A one step mechanism of hydrolysis is utilised by some bacterial enzymes—LEH from *Rhodococcus erythropolis* and TbEH1 from *Mycobacterium tuberculosis* (Arand et al. 2003b; Johansson et al. 2005)—which form an active site containing the catalytic residues Asp-Arg-Asp (Arand et al. 2003a). Compared to the broad substrate spectrum of mEH, all latter enzymes show rather narrow substrate selectivity.

Mammalian α/β hydrolase fold epoxide hydrolases

Microsomal epoxide hydrolase (EC 3.3.2.9)

Gene and protein structure

The human EPHX1 gene is located on the long arm of chromosome 1 and approximately 20 kb in size, composed of eight introns and nine exons, of which exons 2–9 are coding (Falany et al. 1987). In mammals, several alternative non-coding exons 1 exist, that provide the possibility of

¹ In an enzymatic reaction involving a covalent intermediate the Michaelis constant K_m resolves to $K_m = K_D \times k_2 / (k_1 + k_2)$ (where k_1 describes formation of the intermediate, whereas k_2 describes the product formation) and in the case of k_2 being orders of magnitudes smaller than k_1 as mentioned above, k_2 becomes negligible in the denominator, and the ratio K_m / K_D equals the ratio k_2 / k_1 . K_m is therefore orders of magnitudes smaller than the dissociation constant, which is mimicking a high affinity of the enzyme for its substrate as detailed in Arand et al (2003c) Detoxification strategy of epoxide hydrolase—the basis for a threshold in chemical carcinogenesis. EXCLI J 2:22–30.

recruiting alternative promoters for mEH expression (Gaedigk et al. 1997).


EPHX1 translates into a 455 amino acid polypeptide containing an N-terminal membrane anchor (Friedberg et al. 1994b). A crystal structure of human mEH is not available, however, based on the X-ray structure of a related enzyme from *Aspergillus niger* (which lacks the N-terminal membrane anchor) a structural analysis of mammalian mEH (Arand et al. 1999a; Zou et al. 2000) was performed. The typical α/β hydrolase fold is covered by a lid domain, but unique for mEH compared to other α/β hydrolases is an N-terminal meander that clasps around both core and lid domain (Fig. 3a). Because the *Aspergillus* EH represents a dimer, it is intriguing to speculate that human mEH may also exist in dimeric form. The mEH active site was analysed by site directed mutagenesis of mEH protein expressed in *E. coli* (Laughlin et al. 1998; Tzeng et al. 1998) and *S. cerevisiae* (Arand et al. 1996), which identified the catalytic triad as Asp226, Glu404 and His431 and the two tyrosine are represented by residues Tyr299 and 374 (Armstrong and Cassidy 2000). Microsomal EHs are the only epoxide hydrolases containing a glutamate as acidic residue. Replacing Glu with Asp leads to an mEH variant so far not found in the animal kingdom

with a 30-fold increase in the turnover rate (Arand et al. 1999b). This raises the question why evolution would favour the apparently “inefficient” enzyme variant. One explanation might be that a strong enhancement of the mEH turnover rate could have some undesired effects on endogenous EH substrates (e.g. signalling lipid epoxides) with potential side effects for the organism.

Organ and cellular distribution

Microsomal epoxide hydrolase is highly expressed in the liver and other organs such as the lungs, kidneys, intestine, brain, prostate, heart and testes (Coller et al. 2001). Because mEH seems under a complex transcriptional control due to the utilisation of different promoters, the mEH expression level might vary in dependence on tissue and cell type (Gaedigk et al. 1997). The human mEH expression is inducible by a number of compounds including phenobarbitone and *N*-acetylaminofluorene (Fig. 4c) (Astrom et al. 1987; Hassett et al. 1989), effects mediated by the transcription factors Nrf2 (Kwak et al. 2001), GATA-4 (Zhu et al. 2004) and CAR (Merrell et al. 2008). The protein is attached to the cytosolic site of the endoplasmic reticulum membrane with its N-terminal membrane anchor

Fig. 4 The substrate spectrum of microsomal epoxide hydrolase. **a** Substrates for mEH. **b** Inhibitors of microsomal epoxide hydrolase. **c** Inducers of microsomal epoxide hydrolase



(Friedberg et al. 1994a; Holler et al. 1997), which correlates to the membrane topology of CYPs. Some reports though claim a localisation of mEH in the plasma membrane, based on the enzymes possible function in bile acid transport (Zou et al. 2000; von Dippe et al. 2003) which is, however, a matter for debate (Honscha et al. 1995).


Physiological functions

The mEH classically plays a major role in xenobiotic metabolism due to its exceptionally broad substrate selectivity and prominent expression in the liver and other metabolising organs, ensuring widespread defence against potential genotoxic epoxides. Due to the special mechanistic features described above, the mEH is involved in the efficient detoxification of many reactive epoxide intermediates (Armstrong 1987; Arand et al. 2003c) including metabolites of polycyclic aromatic hydrocarbons (Oesch 1973). Generally good substrates for the mEH are lipophilic substituted epoxides of *cis*-configuration such as *cis*-stilbene oxide. Examples for mEH substrates are epoxides derived from anticonvulsive drugs (carbamazepine-10,11-epoxide) (Bellucci et al. 1987), toxic and procarcinogenic compounds such as styrene-7,8-oxide (Oesch 1974), epoxide derivatives of butadiene (Krause et al. 1997), benzene (Snyder et al. 1993), naphthalene, anthracene and other polycyclic aromatic hydrocarbons (Bentley et al. 1976; van Bladeren et al. 1985; Shimada 2006) (Fig. 4a). The breakdown of such potential genotoxic epoxide to less harmful metabolites is an efficient process in the protection of macromolecules from the electrophilic attack of reactive intermediates.

The efficient detoxification of styrene oxide shows the detoxification capacity of human mEH (Oesch et al. 2000). Styrene-7,8-oxide, which is the major genotoxic metabolite of the industrial chemical styrene formed by CYPs in the human liver (Sumner and Fennell 1994), is efficiently metabolised by mEH to its less toxic metabolite phenyl glycol. However, already a low exogenous exposure to styrene oxide (but not styrene) correlates with protein/DNA adduct biomarkers for styrene oxide exposure (Rappaport et al. 1996). This is best explained by the assumption, that endogenously formed styrene oxide is efficiently hydrolysed immediately after generation without leaving the liver, while styrene oxide of exogenous origin first has to reach this organ via the circulation. This hypothesis is compatible with the results from toxicokinetic models regarding styrene and styrene metabolite exposure in rats, mice and humans (Csanady et al. 2003). Furthermore, lung fibroblasts engineered to express human mEH at the same level as the human liver are well protected against the genotoxic effects of styrene-7,8-oxide after extended exposure, in contrast to the corresponding parental cells that lack human mEH (Herrero et al. 1997).

Under some circumstances the mEH is involved in the toxification of its substrates, with potentially fatal outcome. Such a dual role of mEH is highlighted by its important role in both detoxification and bioactivation of the polycyclic aromatic hydrocarbon benzo[a]pyrene (Shou et al. 1996). While the enzyme can detoxify many CYP derived epoxides, in particular bay region dihydrodiol epoxides of PAHs are no substrates for mEH, which consequently display a highly genotoxic potential (Friedberg et al. 1994a). As displayed in Fig. 5 the enzyme catalyses the regioselective addition of water to the 8-position of (7R,8S)-benzo[a]pyrene-7,8-epoxide. The resulting dihydrodiol is still a good substrate for the oxidation at the 9,10-position to result in the ultimate carcinogen (7R,8S,9S,10R)-benzo[a]pyrene-7,8,9,10-tetrahydro-7,8-diol-9,10-epoxide, which is not a substrate for mEH anymore (Holder et al. 1974). A contentious issue still is as to whether mEH is protective or toxifying in the case of PAHs. Analysis in mEH knock out models may produce valuable answers, but it should be kept in mind that the outcome of results may heavily depend on the chosen experimental model. Reduced carcinogenicity of 7,12-dimethyl benz[a]anthracene (DMBA) in mEH knockout versus control animals was shown in a skin tumourigenicity model (Miyata et al. 1999), and reduced immunosuppression of DMBA was reported after systemic application in KO versus control animals (Gao et al. 2007). With another model substrate, such as benzo[a]pyrene, the ratio of formation and elimination of genotoxic metabolites may be different and it is not predictable whether systemic toxicity will be higher or lower in mEH knockout mice compared to control littermates. mEH null mice have further been used to show a protective effect of the enzyme against butadiene (Wickliffe et al. 2007), but genotoxicity and haematotoxicity of benzene are again enhanced in these animals (Recio et al. 2005). Another controversial question is the detoxification capacity of mEH for aflatoxin-B₁-8,9-*exo*-epoxide, the short lived but highly genotoxic metabolite of aflatoxin B₁ produced by *Aspergillus flavus* (a fungus particularly contaminating corn and peanuts). A high incidence of hepatocellular carcinomas is observed in regions with high incidences of hepatitis in combination with high aflatoxin exposure (McGlynn et al. 1995). The turnover rate for aflatoxin-B₁-8,9-*exo*-epoxide with human mEH is rather slow in vitro compared to the spontaneous hydrolysis (Guengerich et al. 1998), but due to the afore mentioned mechanism the protective capacity of mEH may be underestimated. Several studies have connected the susceptibility towards aflatoxin induced hepatocarcinogenesis to polymorphisms in the mEH gene (McGlynn et al. 1995; Wild et al. 2000; McGlynn et al. 2003; Dash et al. 2007). Furthermore, mEH has been reported to provide some protection against the mutagenicity of aflatoxin-B₁-8,9-*exo*-epoxide in recombinant *S. cerevisiae* (Kelly et al. 2002).

Fig. 5 Metabolism of benzo[a]pyrene. The representation shows the metabolic activation of benzo[a]pyrene to benzo[a]pyrene-7,8-dihydrodiol-8,9-epoxide, the ultimate carcinogenic metabolite, which is no substrate for mEH anymore. The other pathways describe metabolic reactions by phase II enzymes leading to detoxification of reactive reaction intermediates



On the other hand, endogenous functions of mEH have long been widely overlooked. Endogenous substrates for mEH are certain steroids like estroside (Fandrich et al. 1995) or androstene oxide, suggesting a role in development. Latest reports also connect mEH to neurodegenerative disorders such as Alzheimers and Parkinsons disease (Liu et al. 2006, 2008). Despite the fact that the sEH is the main enzyme to metabolise numerous endogenous fatty acid derived epoxides (see below), mEH also accepts fatty acid derived epoxides such as epoxystearic acid with high enantioselectivity (Zeldin et al. 1996), EETs (Oliw et al. 1982) or an epoxide of anandamide (Snider et al. 2007), although generally to a much lesser extent than sEH. Therefore, a role of mEH in signalling cascades cannot be excluded, particularly in the case of a high mEH expression in certain organs or cell types.

A number of mEH inhibitors have been developed to investigate mechanistic aspects of epoxide hydrolysis or an involvement of the enzyme in pathophysiology. 1,1,1-Trichloropropene-2,3-oxide was found to be an inhibitor of rodent and human mEH (Papadopoulos et al. 1985) and cyclopropyl oxiranes are competitive reversible inhibitors for mEH (Prestwich et al. 1985) (Fig. 4c). Also the anticonvulsant valpromide was identified as a mEH inhibitor and recently other substituted fatty acid amides (elaidamide) were developed as metabolically stable mEH inhibitors of much higher affinity (Morisseau et al. 2001, 2008).

Polymorphisms

Two prominent genetic polymorphisms (Tyr113His and His139Arg) have been identified in the coding region of mEH (Omiecinski et al. 2000), both displaying ethnic differences. The protein variants resulting from the different haplotypes have been reported to display different half lives (Hassett et al. 1994, 1997), so that these genetic variants may have impact on mEH activity in vivo. mEH polymorphisms may lead to differences in bioactivation of procarcinogens, resulting in altered susceptibilities to cancers of various tissues (Tranah et al. 2005; Lin et al. 2007; Mittal and Srivastava 2007). Studies associating mEH polymorphism with lung cancer have obtained apparently contradictory results (Habalova et al. 2004). However, two meta analysis associated the His113/His139 haplotype (predicted slow activity) with a significantly decreased risk of lung cancer (Lee et al. 2002; Kiyohara et al. 2006). Other studies associate the His113/His139 variant with a protective effect regarding chronic obstructive pulmonary disease (Brogger et al. 2006), as well as a decreased risk of pregnancy induced hypertension (preeclampsia) (Zusterzeel et al. 2001), but on the other hand an increased susceptibility to development of liver cancer after exposure to aflatoxin-B1 (Hengstler et al. 1998; McGlynn et al. 2003) was demonstrated. The His113/His139 variant further has been reported to be more frequent in COPD and lung emphysema patients

as compared to healthy controls (Smith and Harrison 1997). Moreover, several other polymorphisms have been identified in the 5'-flanking region of the mEH promoter region (Raaka et al. 1998).

Soluble epoxide hydrolase (EC 3.3.2.10, EC 3.1.3.76)

Gene and protein structure

The human EPHX2 gene is located on chromosome 8, approximately 54 kb in size, and composed of 19 exons and 18 introns (Sandberg and Meijer 1996). Two alternative ovary specific transcripts EPHX2B and C have recently been described, that both substitute the first two exons of the known sEH sequence (Hennebold et al. 2005; Shkolnik et al. 2007). This results in a sEH protein which lacks essential catalytic components of its N-terminal phosphatase domain (see below), while leaving the epoxide hydrolase domain intact. These alternative transcripts are particularly interesting as the sEH knockout line (Sinal et al. 2000) was constructed by disruption of the first intron, whereas in a second established knock out line (Luria et al. 2007) the exact disruption site is not published. Thus, the knock out may be incomplete in both cases, with respect to the epoxide hydrolase activity of the enzyme.

Mammalian sEH has a primary structure of 554 amino acids (Beetham et al. 1993; Grant et al. 1993; Knehr et al. 1993). One sEH monomer is constituted of two separate catalytic domains—a phosphatase in the N-terminus and the epoxide hydrolase in the C-terminus—separated by a proline rich linker (Fig. 6a). Mammalian sEH is a homodimeric enzyme showing a domain swapped architecture, where the N-terminal domain of one subunit interacts with the C-terminal domain of the other. Both domains are classified within large and separate superfamilies of hydrolases based on structural similarities. The structures of murine (Argiriadi et al. 1999) and human (Gomez et al. 2004) sEH have been solved giving interesting insights into the mechanism of the enzyme. The C-terminal domain (325 amino acids) of each subunit functions as a α/β hydrolase fold epoxide hydrolase as described earlier. The catalytic triad of rodent sEH is composed of the active site residues Asp333, Asp495 and His523 (Pinot et al. 1995; Arand et al. 1996) and the two tyrosines Tyr382 and Tyr465 (Argiriadi et al. 1999).

The smaller N-terminal domain instead displays a recently discovered phosphatase activity (Cronin et al. 2003; Newman et al. 2003). This phosphatase domain belongs to a distinct family of HADs, comprising a number of phosphatases, dehalogenases and other hydrolases (Koonin and Tatusov 1994; Beetham et al. 1995). Albeit an overall low sequence similarity, all enzymes of the HAD superfamily possess a structurally conserved rosmannoid

fold (core domain), containing four loops that form the catalytic scaffold (Fig. 6a). Loop 1 contains the catalytic Asp nucleophile followed by a second aspartic acid (Wang et al. 2002; Allen and Dunaway-Mariano 2004). Loops 2 and 3 orientate the phosphate substrate with residues Ser/Thr and Lys/Arg, whereas loop 4 contains the Mg^{2+} binding pocket formed by two aspartic acids (Baker et al. 1998; Morais et al. 2000; Wang et al. 2001). Additionally, the HAD enzymes are divided into three subfamilies I–III due to the presence and location of an additional cap domain. Class I HADs such as the sEH phosphatase contain an insertion between loop 1 and 2 of the core domain (Lahiri et al. 2004, 2006). This cap domain is implicated in solvent protection of the active site as well as substrate selectivity (Selengut 2001). Based on structural similarities with other members of the HAD family and site directed mutagenesis we identified the composition of the active site as Asp9, Asp11, Thr123, Asn124, Lys160, Asp184, Asp185 and Asn189. We recently investigated the catalytic mechanism of dephosphorylation, using kinetic evaluation of active site mutants and LC–MS/MS analysis of the phosphorylated enzyme intermediate. In the first step in the dephosphorylation reaction, the phosphate residue is transferred from the substrate to Asp9 which acts as the catalytic nucleophile (Fig. 6b, c). In a second step the phosphoenzyme intermediate is hydrolysed via nucleophilic attack of an activated water molecule (Cronin et al. 2008).

Cellular distribution

The sEH is expressed in almost every organ such as liver, lungs, kidneys, heart, brain and ovary (Enayetallah et al. 2004; Sura et al. 2008). The enzyme is mainly localised in the cell cytosol, but in some cell types sEH shows a dual localisation, both cytosolic and peroxisomal. This is due to an imperfect C-terminal peroxisomal targeting sequence (PTS-1) (Arand et al. 1991; Mullen et al. 1999) and in dependence of protein expression level and quaternary structure (Enayetallah et al. 2006a; Luo et al. 2008).

In rodents, sEH expression is inducible by peroxisome proliferators (PPs, a number of structurally diverse compounds including hypolipidemic drugs such as fibrates and phthalates) (Fig. 7c), an effect mediated by the transcription factor peroxisome proliferator activated receptor (PPAR) (Oesch et al. 1986; Lundgren et al. 1987; Johansson et al. 1995), which suggests a possible role of sEH in PP induced liver cancerogenesis. A PPAR mediated induction of sEH in humans has not yet been detected. Recently, an AP1 mediated regulation of sEH by Angiotensin-II has been shown (Ai et al. 2007), and further Monti et al. (2008) identified an sEH genetic variant associated with heart failure in rats, which is characterised by the existence of a new AP1-binding site in the promoter region.




Fig. 6 Three dimensional structure of soluble epoxide hydrolase and catalytic mechanism of the sEH phosphatase. **a** Structure model of one subunit of the homodimeric soluble epoxide hydrolase, consisting of an N-terminal phosphatase (Core domain represented in *green* and lid domain in *gold*) and the C-terminal epoxide hydrolase domain (α/β hydrolase fold displayed in *red* and lid domain in *blue*). **b** Stereo view


of the sEH phosphatase active site, with the catalytic amino acids highlighted. The structural model was prepared using the program PyMOL (v9.07; DeLano Scientific LLC, San Carlos, CA, USA) based on the coordinates from the PDB data file 1CQZ. **c** Two step mechanism of dephosphorylation as described in detail in the text

Physiological functions

Most established sEH functions are currently assigned to the epoxide hydrolase activity. In xenobiotic metabolism the sEH complements the mEH spectrum of substrates for

an efficient turnover, in that it hydrolyses *trans*-substituted slender epoxides and shows complementary substrate specificity to mEH (Morisseau and Hammock 2005), including potentially harmful epoxides (Arand et al. 2003a). Typical substrates are *trans*-stilbene oxide, and in particular fatty

Fig. 7 The substrate spectrum of soluble epoxide hydrolase. **a** Substrates of soluble epoxide hydrolase. **b** Inhibitors of soluble epoxide hydrolase. **c** Inducers of soluble epoxide hydrolase. **d** Substrates of the sEH phosphatase



acid derived substrates (Fig. 7a). Fatty acids such as *cis*-9,10-epoxystearic acid have been identified as excellent substrates for mammalian sEH (Zeldin et al. 1993; Summerer et al. 2002), but in contrast to soybean sEH or mammalian mEH with little enantioselectivity or enantioconvergence (Summerer et al. 2002).

In contrast to a classical role in detoxification processes, the major physiological role of sEH certainly is the metabolism of fatty acid derived epoxides to the corresponding diols. The organism utilises a large number of endogenous epoxides—mainly derived from arachidonic acid (EETs) and linoleic acid (leukotoxin)—as important signalling molecules and physiological regulators. One of the first reports of physiological relevance was the sEH catalysed turnover of leukotoxin to the actual toxic metabolite

leukotoxin diol, causing multiple organ failure and adult respiratory distress syndrome after severe body burns (Moghaddam et al. 1996). Human sEH is the primary enzyme that metabolises such endogenous epoxides (Moghaddam et al. 1996; Morisseau and Hammock 2005; Newman et al. 2005), although other mammalian epoxide hydrolases may play a physiological role under certain conditions.

Due to its important role in the lipid metabolism of EETs, the sEH has recently evolved as a target for the treatment of hypertension (Fang et al. 2001; Imig 2005; Newman et al. 2005), inflammatory diseases (Liu et al. 2005; Schmelzer et al. 2005; Inceoglu et al. 2006), and a novel treatment of pain, diabetes and stroke (Ohtoshi et al. 2005; Schmelzer et al. 2006; Spector and Norris 2007; Zhang

et al. 2007). The formation of *cis*-EETs is catalysed by various CYPs and sEH hydrolyses all EET regioisomers with the order of preference being 14,15-EET > 11,12-EET > 8,9-EET > 5,6-EET. The breakdown of EETs by sEH is in general believed to be a deactivation process. EETs were identified as endothelium derived hyperpolarisation factor, causing prostacyclin and NO independent vasodilation in vascular beds (Fisslthaler et al. 1999), which created massive interest in these lipid derived epoxides. EETs (released from the endothelium) act on large conductance calcium activated K⁺ channels (BKCa) on vascular smooth muscle cells leading to hyperpolarisation and vasodilation (Hu and Kim 1993; Li and Campbell 1997) by a mechanism including G_{zs} activation (Li and Campbell 1997). To complicate matters, the different EET regioisomers may have opposing effects dependant on the cell type and experimental set up, and EET effects might be stereoselective (Imig et al. 1996; Falck et al. 2003; Pomposiello et al. 2003; Newman et al. 2005). Despite contradictory reports on the influence of sEH gene disruption on basal blood pressure (possibly due to compensation by the vasoconstrictor 20-HETE) in sEH null mice (Sinal et al. 2000; Luria et al. 2007), several experimental hypertensive models have indeed shown a role of EETs in blood pressure regulation and end organ protection, using specific sEH inhibitors (Imig et al. 2002; Zhao et al. 2004; Fang 2006; Li et al. 2008; Zhang et al. 2008a). Very recently the sEH has been shown to be a susceptibility factor for heart failure in a rat model (Monti et al. 2008). Evidence is accumulating that EETs also display anti-inflammatory properties, by a mechanism based on disruption of the proinflammatory Nf_κb signalling pathway. sEH inhibitors attenuated tobacco smoke induced lung inflammation in rats (Smith et al. 2005), and sEH KO mice also showed a survival advantage following acute systemic inflammation induced by lipopolysaccharides, effects that might at least in part be mediated by PPAR γ (Liu et al. 2005; Inceoglu et al. 2006; Schmelzer et al. 2006). The latter studies also pointed to an antinociceptive effect of EETs, as administration of sEH inhibitors decrease LPS-induced thermal hyperalgesia and mechanical allodynia in a systemic model of inflammatory pain (Inceoglu et al. 2006), an effect enhanced by coadministration of sEH inhibitors and common non-steroidal anti-inflammatory drugs (Schmelzer et al. 2006). Very recently 14,15-EET was shown to mediate its antinociceptive effect via the μ - and δ -opioid receptor pathway (Terashvili et al. 2008). Because EETs play important roles in the brain—including regulation of cerebral blood flow and protection from ischemic brain injury—sEH has emerged as a potential pharmacological target for the treatment of stroke (Zhang et al. 2007, 2008b; Gschwendtner et al. 2008). Finally, several studies point to an effect of EETs on cell proliferation (Potente et al. 2003), migration (Sun et al.

2002) and angiogenesis (Michaelis et al. 2005), actions which seem mediated through several signalling pathways including p38 MAPK, PI₃K Akt or PKA and in dependence of the species, the type of endothelium and/or the EET regioisomer (Spector and Norris 2007).

Due to the various described endogenous functions of EETs, inhibitors for sEH (sEHI) have been developed over the past decade, aiming in particular at new therapeutics for the treatment of hypertension. sEHIs comprise of several chemical classes such as chalcone oxide derivatives (Morisseau et al. 1998), trans-3-phenylglycidols (Dietze et al. 1991, 1993), as well as urea and carbamate-based inhibitors (Morisseau et al. 2002, 2006; Kim et al. 2004, 2007) (Fig. 7c).

In contrast, the physiological role of the recently discovered phosphatase activity of sEH is much less clear, but it further highlights the role of this enzyme in regulatory processes. The sEH phosphatase so far accepts the generic substrate 4-NPP, some lipid phosphates (Newman et al. 2003; Tran et al. 2005), as well as isoprenoid phosphates (Enayetallah et al. 2006b; Enayetallah and Grant 2006). Of these *threo*-9,10-phosphonoxy-hydroxy-octadecanoic acid as well as the monophosphates of farnesol and geraniol are among the best substrates (Fig. 7d). Because isoprenoid phosphates are intermediate metabolites at the branching point of cholesterol biosynthesis as well as precursors for protein prenylation, the sEH phosphatase is possibly connected to cholesterol biosynthesis, protein prenylation and metabolism of certain lipid phosphates. Due to the dual localisation of sEH in cell cytosol and peroxisomes, the physiological target of the sEH phosphatase activity might be organelle specific. Recently two ovary specific alternative transcripts—EPHX2B and C—of the sEH have been identified (Hennebold et al. 2005; Shkolnik et al. 2007) both of which are shortened at the N-terminus leading to an inactive phosphatase domain. EPHX2C is found in the ovary at the highest level of expression occurring during the luteal phase of a stimulated oestrous cycle, suggesting a role of the sEH phosphatase in hormonal regulation.

Efforts are being made to develop specific sEH phosphatase inhibitors (Tran et al. 2005; Enayetallah et al. 2006a), but due to the large collection of endogenous phosphatases this seems to be a challenging task.

Polymorphisms

A number of non-synonymous nucleotide polymorphisms (Lys55Arg, Arg103Cys, Cys154Tyr, Arg287Gln, Val422Ala and Glu470Gly, insertion Arg402ArgArg) have been identified for human sEH (Sandberg et al. 2000; Saito et al. 2001; Przybyla-Zawislak et al. 2003) that affect the protein coding sequence as well as enzymatic activity. Of these, sEH variant Lys55Arg, which has increased epoxide hydrolase

activity, is associated with coronary artery disease, especially in Caucasian, but not African American cigarette smokers (Lee et al. 2006). The most significant polymorphism however is represented by sEH variant Arg287Gln which seems to be associated with a number of diseases. The Arg287Gln mutation results in sEH protein with reduced stability and reduced epoxide hydrolase activity (Przybyla-Zawislak et al. 2003), as well as decreased ability of homodimer formation (Srivastava et al. 2004) and therefore facilitated peroxisomal import (Luo et al. 2008). The reported results on phosphatase activity are inconsistent, increased phosphatase activity (Enayetallah and Grant 2006) as well as decreased phosphatase activity of the Arg287Gln mutant as compared to the WT enzymes using isoprenoid phosphates and/or generic substrate (Srivastava et al. 2004) are described. The allelic frequencies for the Arg287Gln allele are 5% for Europeans, 20% for Asians and 8% for Africans. The Arg287Gln allele was associated with increased risks for coronary artery calcification in African Americans, but not caucasians (Fornage et al. 2004; Burdon et al. 2008), insulin resistance in diabetes type II patients (Ohtoshi et al. 2005), ischemic stroke (Koerner et al. 2007), as well as hypercholesterolemia (Sato et al. 2004) in carriers of a LDL-receptor mutation.

EH 3 and 4

The genes EPHX3 and 4 are closely related, the corresponding gene products EH3 and EH4 are polypeptides of 360 and 362 amino acids in length, respectively. EH 3 and 4 show a sequence identity of 45%, with higher sequence similarity to sEH than mEH (Fig. 2). Both proteins contain a predicted N-terminal membrane anchor. No report of an endogenous substrate for EH3 and 4 is available yet, but at least EH3 represents a functional epoxide hydrolase. Substrate spectrum as well as expression pattern of both enzymes are currently being assessed in our group (manuscript in preparation).

The first hints to cellular distribution of EH3 and 4 stem from EST and microarray database analysis, according to which expression of EH 3 is generally low but found in lung, tongue and skin. A recent study of the human epidermal transcriptome demonstrated a high expression of EH3 in human granular keratinocytes (Toulza et al. 2007), and a human/mouse conserved coexpression analysis to predict human disease genes suggests EPHX3 as candidate gene for ichthyosis (Ala et al. 2008). Moreover, EPHX3 gains some attention as methylation marker for cancer prognosis. In many cancers tumour suppressor genes are inactivated by methylation silencing of their promoter regions. CpG islands in the promoter region of EPHX3 are methylated in melanoma cell lines compared to cultured human epidermal melanocytes (Furuta et al. 2006), as well as in primary gastric cancers and multiple gastric cancer cell lines (Yamashita

et al. 2006). EPHX3 was further identified as candidate marker for prostate cancer prognosis by showing increased methylation levels in patients with early PSA recurrence compared to non-recurrent patients (Cottrell et al. 2007). These results indicate a transcriptional silencing of the EPHX3 gene in some cancer events.

In contrast, an expression of EH4 is reported mainly in the brain and eyes. Studies in our group (manuscript in preparation) and expression analysis of rat brain (Stansberg et al. 2007) confirm these findings.

Taken together, the expression pattern suggests a role for both enzymes in the regulation of endogenous functions rather than a role in xenobiotic metabolism. Future investigation will show the exact physiological function of both enzymes.

MEST

The paternally expressed gene 1/mesoderm specific transcript (peg1/MEST) is an imprinted gene that is widely expressed in mammalian tissue (Kobayashi et al. 1997). As an imprinted gene, peg1 shows a promoter methylation pattern that reflects a strict parent-of-origin-specific differential methylation (Lefebvre et al. 1997). Expression of peg1/MEST stays imprinted in adult mice and humans and is high in the nervous system, but an occasional loss of imprinting occurs in cases of invasive breast cancer (Pedersen et al. 1999) and lung adenocarcinoma (Nakanishi et al. 2004). The 335 amino acid polypeptide has a predicted N-terminal membrane anchor. An epoxide hydrolase activity of peg1/MEST still needs to be confirmed, however the protein shows significant sequence similarity to α/β fold epoxide hydrolases (Kaneko-Ishino et al. 1995). MEST contains one conserved, probably epoxide-coordinating tyrosine in the primary sequence and two related epoxide hydrolases from *M. tuberculosis* do indeed show weak epoxide hydrolase activity (personal observations).

A physiological function of MEST has not yet been established, but the fact that MEST is an imprinted gene suggests an important role in development. Targeted disruption of peg1/MEST leads to growth retardation and behavioural effects (Lefebvre et al. 1997). Very recently MEST has been associated with fat mass expansion in response to a high fat diet, due to an up to 50-fold upregulation of mRNA and protein levels in adipose tissue (Nikonova et al. 2008), which further suggest a role of MEST in lipid metabolism.

Other mammalian epoxide hydrolases

Hepoxilin epoxide hydrolase (EC 3.3.2.7)

Hepoxilin epoxide hydrolase was partly purified from rat liver cytosol (Pace-Asciak and Lee 1989) and discriminated

from sEH due to its size of 53 kDa and substrate selectivity for hepoxilin A₃, while showing only marginal activity towards leukotriene or styrene oxide. Because Hepoxilin EH is not cloned to date the question remains whether this enzyme belongs to the family of α/β hydrolase fold EHs. A function in xenobiotic metabolism is—despite an expression in the liver—unlikely, due to the rather specific substrate spectrum.

Hepoxilins (hydroxyepoxy eicosanoids) are widely distributed in mammals (Newman et al. 2005; Nigam et al. 2007). The *trans*-epoxides hepoxilin A₃ and B₃ are derived from the action of 12-lipoxygenase on arachidonic acid and may be degraded by the action of an EH (to the corresponding trihydroxy metabolite trioxilin) or conjugation with glutathione (Laneuville et al. 1991). Hepoxilins formed in rat pancreatic islets enhance the glucose dependant secretion of insulin (Pace-Asciak and Martin 1984). Hepoxilins facilitate calcium transport (Derewlany et al. 1984), and they are further formed in the brain with synaptic neuromodulatory actions on hippocampal neurons by hyperpolarisation and enhancement of the inhibitory postsynaptic potential (Pace-Asciak et al. 1990, 1995). Hepoxilin signalling is most likely receptor mediated, an assumption based on the identification of a hepoxilin binding protein in human neutrophils (Reynaud et al. 1999). Hepoxilin A₃ seems to be a key regulator of neutrophil migration in response to an inflammation response (Mrsny et al. 2004). Due to the occurrence of increased hepoxilins and trioxilin levels in psoriatic lesions the lipids are thought to act proinflammatory in the skin (Anton et al. 1998). Moreover, mutations in the hepoxilin generating epidermal lipoxygenase pathway are associated with a congenital form of ichthyosis. This suggests an involvement of these lipid mediators in epidermal differentiation and skin barrier function (Brash et al. 2007; Epp et al. 2007; Yu et al. 2007).

Nonetheless, hepoxilin A₃ and B₃ are excellent substrates for mammalian sEH (manuscript in preparation). The enzyme is further expressed in hepoxilin generating tissue, which strongly suggests a physiological function of sEH in hepoxilin metabolism. The regulation of these signalling molecules might occur by both enzymes depending on cell type/tissue or regulatory state.

Cholesterol epoxide hydrolase (EC 3.3.2.11)

The existence of an epoxide hydrolase specific for cholesterol-5 α ,6 α -epoxide was already described 1974 (Aringer and Eneroth 1974; Chan and Black 1976; Oesch et al. 1984). ChEH is widely distributed in mammals (Astrom et al. 1986), but little is known about the enzyme and no gene sequence is available. An induction of ChEH has been reported in rodents exposed to the PPAR α agonist clofibrate (Finley and Hammock 1988), like as for sEH. Although

also present in microsomal cell fractions, ChEH activity is distinct from mEH (Oesch et al. 1984). Moreover, several lines of evidence suggest that ChEH does not represent a α,β -hydrolase fold EH. Size exclusion analysis of the native enzyme partly purified from mouse liver suggested ChEH to be smaller than a typical α,β hydrolase fold epoxide hydrolase (Watabe et al. 1986). In contrast to mEH and sEH the enzyme could not be labelled covalently with ¹⁴C-cholesterol-5 α ,6 α -epoxide. These results led to the speculation that ChEH might hydrolyse its substrate via a different mechanism and represents the first mammalian EH member similar to the recently described bacterial LEH (EC. 3.3.2.8) from *Rhodococcus erythropolis* (Barbirato et al. 1998). The LEH hydrolyses its substrate in a single step mechanism and further shares structural similarity to an epoxide hydrolase from *Mycobacterium tuberculosis* (TbEH1). Strikingly, this TbEH1 is the only other enzyme able to facilitate such a bulky substrate like cholesterol-5,6-epoxide (Arand et al. 2003a, b; Johansson et al. 2005).

An oxidation of cholesterol proceeds as part of the lipid peroxidation process in membranes (Astrom et al. 1986), and ChEH functions in conversion of 5 α ,6 α -epoxicholestane-3 β -ol and 5 β ,6 β -epoxicholestane-3 β -ol to cholestane-3 β ,5 α ,6 β -triol (Watabe et al. 1981). Some toxicological interest arose from cholesterol epoxide which was reported to act as a weak direct acting mutagen (Sevanian and Peterson 1984, 1986). Cholesterol epoxide was further the suspected dermatocarcinogen in hairless mice irradiated by UV. The mutagenicity of cholesterol epoxide in V79 Chinese hamster lung fibroblasts (Black and Douglas 1972; Reddy and Wynder 1977; Sevanian and Peterson 1984) suggests that the ChEH might play a role in protecting cells from these steroid toxicants, however, the cholesterol epoxides are quiet stable and the corresponding cholestantriols are themselves cytotoxic (Wilson et al. 1997; Vejux et al. 2007). Further, cholesterol epoxides are implicated in apoptosis (Ryan et al. 2004), as well as vascular function and coronary artery disease (Rimner et al. 2005) because they are found upregulated in arteriosclerotic lesions. Only a complete characterisation of ChEH can help to fully understand the physiological role of this enzyme.

Leukotriene A₄ hydrolase (EC 3.3.2.6)

As an atypical epoxide hydrolase Leukotriene A₄ hydrolase will only be briefly addressed, and we refer to some recent excellent reviews (Chen et al. 2004; Haeggstrom 2004; Newman et al. 2005; Haeggstrom et al. 2007). The enzyme has been cloned (Funk et al. 1987), purified from rat and human erythrocytes and neutrophils (Radmark et al. 1984; Evans et al. 1985; McGee and Fitzpatrick 1985), and the crystal structure has been solved (Tsuge et al. 1994; Thunnissen et al. 2001). LTA₄H is not related to mEH, sEH or

other α/β -hydrolases, instead the bifunctional metalloprotein LTA₄H possesses an epoxide hydrolase as well as an aminopeptidase activity (Haeggstrom et al. 1990; Minami et al. 1990).

The aminopeptidase activity is of presently unknown biological function, although limited peptide substrates have been described (Griffin et al. 1992). LTA₄H hydrolyses leukotriene A₄ which is generated via the 5-lipoxygenase pathway from arachidonic acid—not like sEH to the vicinal diol—but to LTB₄, a non-vicinal 5,12-diol (McGee and Fitzpatrick 1985). LTB₄ is a potent chemotactic agent for neutrophils, eosinophils, monocytes and T-Cells, which all play key roles in immune response. Therefore LTA₄H is strongly linked to the pathophysiology of arteriosclerosis, myocardial infarction and stroke (Haeggstrom 2004). Because LTA₄H generally functions as a proinflammatory enzyme, LTA₄H has as of late attracted attention as a target for cancer prevention. LTA₄H inhibitors prevented DMBA induced oral carcinogenesis in hamsters (Sun et al. 2006) and inhibited proliferation as well as induced apoptosis in pancreatic adenocarcinomas (Zhou et al. 2007).

Outlook

Albeit the important role of epoxide hydrolases—mEH in particular—in xenobiotic metabolisms it is now evident that epoxide hydrolases have vital roles in endogenous regulatory processes. This seems also the case for the newly identified potential epoxide hydrolases. Only a throughout characterisation of these enzymes including an evaluation of the substrate spectrum and identification of cellular EH substrate receptors will clear their physiological function. The potential of mammalian epoxide hydrolases as drug targets is highlighted by the growing interest in the development of effective epoxide hydrolase inhibitors.

References

- Ai D, Fu Y, Guo D, Tanaka H, Wang N, Tang C, Hammock BD, Shyy JY, Zhu Y (2007) Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo. *Proc Natl Acad Sci USA* 104:9018–9023. doi:10.1073/pnas.0703229104
- Ala U, Piro RM, Grassi E, Damasco C, Silengo L, Oti M, Provero P, Di Cunto F (2008) Prediction of human disease genes by human-mouse conserved coexpression analysis. *PLoS Comput Biol* 4:e1000043. doi:10.1371/journal.pcbi.1000043
- Allen KN, Dunaway-Mariano D (2004) Phosphoryl group transfer: evolution of a catalytic scaffold. *Trends Biochem Sci* 29:495–503. doi:10.1016/j.tibs.2004.07.008
- Anton R, Puig L, Esgleyes T, de Moragas JM, Vila L (1998) Occurrence of hepxilins and trioxilins in psoriatic lesions. *J Invest Dermatol* 110:303–310. doi:10.1046/j.1523-1747.1998.00159.x
- Arand M, Knehr M, Thomas H, Zeller HD, Oesch F (1991) An impaired peroxisomal targeting sequence leading to an unusual bicompartmental distribution of cytosolic epoxide hydrolase. *FEBS Lett* 294:19–22. doi:10.1016/0014-5793(91)81333-4
- Arand M, Grant DF, Beetham JK, Friedberg T, Oesch F, Hammock BD (1994) Sequence similarity of mammalian epoxide hydrolases to the bacterial haloalkane dehalogenase and other related proteins. Implication for the potential catalytic mechanism of enzymatic epoxide hydrolysis. *FEBS Lett* 338:251–256. doi:10.1016/0014-5793(94)80278-5
- Arand M, Wagner H, Oesch F (1996) Asp333, Asp495, and His523 form the catalytic triad of rat soluble epoxide hydrolase. *J Biol Chem* 271:4223–4229. doi:10.1074/jbc.271.8.4223
- Arand M, Hemmer H, Durk H, Baratti J, Archelas A, Furstoss R, Oesch F (1999a) Cloning and molecular characterization of a soluble epoxide hydrolase from *Aspergillus niger* that is related to mammalian microsomal epoxide hydrolase. *Biochem J* 344(Pt 1):273–280. doi:10.1042/0264-6021.3440273
- Arand M, Muller F, Mecky A, Hinz W, Urban P, Pompon D, Kellner R, Oesch F (1999b) Catalytic triad of microsomal epoxide hydrolase: replacement of Glu404 with Asp leads to a strongly increased turnover rate. *Biochem J* 337(Pt 1):37–43. doi:10.1042/0264-6021:3370037
- Arand M, Cronin A, Oesch F, Mowbray SL, Jones TA (2003a) The telltale structures of epoxide hydrolases. *Drug Metab Rev* 35:365–383. doi:10.1081/DMR-120026498
- Arand M, Hallberg BM, Zou J, Bergfors T, Oesch F, van der Werf MJ, de Bont JA, Jones TA, Mowbray SL (2003b) Structure of Rhodococcus erythropolis limonene-1, 2-epoxide hydrolase reveals a novel active site. *EMBO J* 22:2583–2592. doi:10.1093/emboj/cdg275
- Arand M, Herrero Plana ME, Hengstler JG, Lohmann M, Cronin A, Oesch F (2003c) Detoxification strategy of epoxide hydrolase—the basis for a threshold in chemical carcinogenesis. *EXCLI J* 2:22–30
- Argiriadi MA, Morisseau C, Hammock BD, Christianson DW (1999) Detoxification of environmental mutagens and carcinogens: structure, mechanism, and evolution of liver epoxide hydrolase. *Proc Natl Acad Sci USA* 96:10637–10642. doi:10.1073/pnas.96.19.10637
- Aringer L, Eneroth P (1974) Formation and metabolism in vitro of 5, 6-epoxides of cholesterol and beta-sitosterol. *J Lipid Res* 15:389–398
- Armstrong RN (1987) Enzyme-catalyzed detoxication reactions: mechanisms and stereochemistry. *CRC Crit Rev Biochem* 22:39–88. doi:10.3109/10409238709082547
- Armstrong RN, Cassidy CS (2000) New structural and chemical insight into the catalytic mechanism of epoxide hydrolases. *Drug Metab Rev* 32:327–338. doi:10.1081/DMR-100102337
- Astrom A, Eriksson M, Eriksson LC, Birberg W, Pilotti A, DePierre JW (1986) Subcellular and organ distribution of cholesterol epoxide hydrolase in the rat. *Biochim Biophys Acta* 882:359–366
- Astrom A, Maner S, DePierre JW (1987) Induction of liver microsomal epoxide hydrolase, UDP-glucuronyl transferase and cytosolic glutathione transferase in different rodent species by 2-acetylaminofluorene or 3-methylcholanthrene. *Xenobiotica* 17:155–163
- Baker AS, Ciocci MJ, Metcalf WW, Kim J, Babbitt PC, Wanner BL, Martin BM, Dunaway-Mariano D (1998) Insights into the mechanism of catalysis by the P-C bond-cleaving enzyme phosphonoacetaldehyde hydrolase derived from gene sequence analysis and mutagenesis. *Biochemistry* 37:9305–9315. doi:10.1021/bi972677d
- Barbirato F, Verdoes JC, de Bont JA, van der Werf MJ (1998) The Rhodococcus erythropolis DCL14 limonene-1, 2-epoxide hydrolase gene encodes an enzyme belonging to a novel class of epoxide hydrolases. *FEBS Lett* 438:293–296. doi:10.1016/S0014-5793(98)01322-2

- Beetham JK, Tian T, Hammock BD (1993) cDNA cloning and expression of a soluble epoxide hydrolase from human liver. *Arch Biochem Biophys* 305:197–201. doi:10.1006/abbi.1993.1411
- Beetham JK, Grant D, Arand M, Garbarino J, Kiyosue T, Pinot F, Oesch F, Belknap WR, Shinozaki K, Hammock BD (1995) Gene evolution of epoxide hydrolases and recommended nomenclature. *DNA Cell Biol* 14:61–71
- Bellucci G, Berti G, Chiappe C, Lippi A, Marioni F (1987) The metabolism of carbamazepine in humans: steric course of the enzymatic hydrolysis of the 10, 11-epoxide. *J Med Chem* 30:768–773. doi:10.1021/jm00388a004
- Bentley P, Schmassmann H, Sims P, Oesch F (1976) Epoxides derived from various polycyclic hydrocarbons as substrates of homogeneous and microsome-bound epoxide hydratase. A general assay and kinetic properties. *Eur J Biochem* 69:97–103. doi:10.1111/j.1432-1033.1976.tb10862.x
- Black HS, Douglas DR (1972) A model system for the evaluation of the role of cholesterol-oxide in ultraviolet carcinogenesis. *Cancer Res* 32:2630–2632
- Brash AR, Yu Z, Boeglin WE, Schneider C (2007) The hepxilin connection in the epidermis. *FEBS J* 274:3494–3502. doi:10.1111/j.1742-4658.2007.05909.x
- Brogger J, Steen VM, Eiken HG, Gulsvik A, Bakke P (2006) Genetic association between COPD and polymorphisms in TNF, ADRB2 and EPHX1. *Eur Respir J* 27:682–688. doi:10.1183/09031936.06.00057005
- Burdon KP, Lehtinen AB, Langefeld CD, Carr JJ, Rich SS, Freedman BI, Herrington D, Bowden DW (2008) Genetic analysis of the soluble epoxide hydrolase gene, EPHX2, in subclinical cardiovascular disease in the Diabetes Heart Study. *Diab Vasc Dis Res* 5:128–134. doi:10.3132/dvdr.2008.021
- Chan JT, Black HS (1976) Distribution of cholesterol-5 α , 6 α -epoxide formation and its metabolism in mouse skin. *J Invest Dermatol* 66:112–116. doi:10.1111/1523-1747.ep12481460
- Chen X, Wang S, Wu N, Yang CS (2004) Leukotriene A4 hydrolase as a target for cancer prevention and therapy. *Curr Cancer Drug Targets* 4:267–283. doi:10.2174/1568009043333041
- Coller JK, Fritz P, Zanger UM, Siegle I, Eichelbaum M, Kroemer HK, Murdter TE (2001) Distribution of microsomal epoxide hydrolase in humans: an immunohistochemical study in normal tissues, and benign and malignant tumours. *Histochem J* 33:329–336. doi:10.1023/A:1012414806166
- Cottrell S, Jung K, Kristiansen G, Eltze E, Semjonow A, Ittmann M, Hartmann A, Stamey T, Haefliger C, Weiss G (2007) Discovery and validation of 3 novel DNA methylation markers of prostate cancer prognosis. *J Urol* 177:1753–1758. doi:10.1016/j.juro.2007.01.010
- Cronin A, Mowbray S, Durk H, Homburg S, Fleming I, Fisslthaler B, Oesch F, Arand M (2003) The N-terminal domain of mammalian soluble epoxide hydrolase is a phosphatase. *Proc Natl Acad Sci USA* 100:1552–1557. doi:10.1073/pnas.0437829100
- Cronin A, Homburg S, Durk H, Richter I, Adamska M, Frere F, Arand M (2008) Insights into the catalytic mechanism of human sEH phosphatase by site-directed mutagenesis and LC-MS/MS analysis. *J Mol Biol* 383:627–640. doi:10.1016/j.jmb.2008.08.049
- Csanady GA, Kessler W, Hoffmann HD, Filser JG (2003) A toxicokinetic model for styrene and its metabolite styrene-7, 8-oxide in mouse, rat and human with special emphasis on the lung. *Toxicol Lett* 138:75–102. doi:10.1016/S0378-4274(02)00409-5
- Dash B, Afriyie-Gyawu E, Huebner HJ, Porter W, Wang JS, Jolly PE, Phillips TD (2007) Determinants of the variability of aflatoxin-albumin adduct levels in Ghanaians. *J Toxicol Environ Health A* 70:58–66. doi:10.1080/15287390600748880
- Derewlany LO, Pace-Asciak CR, Radde IC (1984) Hepoxilin A, hydroxyepoxide metabolite of arachidonic acid, stimulates transport of ⁴⁵Ca across the guinea pig visceral yolk sac. *Can J Physiol Pharmacol* 62:1466–1469
- Dietze EC, Kuwano E, Casas J, Hammock BD (1991) Inhibition of cytosolic epoxide hydrolase by trans-3-phenylglycidols. *Biochem Pharmacol* 42:1163–1175. doi:10.1016/0006-2952(91)90250-9
- Dietze EC, Stephens J, Magdalou J, Bender DM, Moyer M, Fowler B, Hammock BD (1993) Inhibition of human and murine cytosolic epoxide hydrolase by group-selective reagents. *Comp Biochem Physiol B* 104:299–308. doi:10.1016/0305-0491(93)90372-C
- Elfstrom LT, Widersten M (2006) Implications for an ionized alkyl-enzyme intermediate during STEH1-catalyzed trans-stilbene oxide hydrolysis. *Biochemistry* 45:205–212. doi:10.1021/bi051893g
- Enayetallah AE, French RA, Thibodeau MS, Grant DF (2004) Distribution of soluble epoxide hydrolase and of cytochrome P450 2C8, 2C9, and 2J2 in human tissues. *J Histochem Cytochem* 52:447–454
- Enayetallah AE, Grant DF (2006) Effects of human soluble epoxide hydrolase polymorphisms on isoprenoid phosphate hydrolysis. *Biochem Biophys Res Commun* 341:254–260. doi:10.1016/j.bbrc.2005.12.180
- Enayetallah AE, French RA, Barber M, Grant DF (2006a) Cell-specific subcellular localization of soluble epoxide hydrolase in human tissues. *J Histochem Cytochem* 54:329–335. doi:10.1369/jhc.5A6808.2005
- Enayetallah AE, French RA, Grant DF (2006b) Distribution of soluble epoxide hydrolase, cytochrome P450 2C8, 2C9 and 2J2 in human malignant neoplasms. *J Mol Histol* 37:133–141. doi:10.1007/s10735-006-9050-9
- Epp N, Furstenberger G, Muller K, de Juanes S, Leitges M, Hausser I, Thieme F, Liebisch G, Schmitz G, Krieg P (2007) 12R-lipoxygenase deficiency disrupts epidermal barrier function. *J Cell Biol* 177:173–182. doi:10.1083/jcb.200612116
- Evans JF, Dupuis P, Ford-Hutchinson AW (1985) Purification and characterisation of leukotriene A4 hydrolase from rat neutrophils. *Biochim Biophys Acta* 840:43–50
- Falany CN, McQuiddy P, Kasper CB (1987) Structure and organization of the microsomal xenobiotic epoxide hydrolase gene. *J Biol Chem* 262:5924–5930
- Falck JR, Krishna UM, Reddy YK, Kumar PS, Reddy KM, Hittner SB, Deeter C, Sharma KK, Gauthier KM, Campbell WB (2003) Comparison of vasodilatory properties of 14, 15-EET analogs: structural requirements for dilation. *Am J Physiol Heart Circ Physiol* 284:H337–H349
- Fandrich F, Degiuli B, Vogel-Bindel U, Arand M, Oesch F (1995) Induction of rat liver microsomal epoxide hydrolase by its endogenous substrate 16 α , 17 α -epoxyestra-1, 3, 5-trien-3-ol. *Xenobiotica* 25:239–244
- Fang X (2006) Soluble epoxide hydrolase: a novel target for the treatment of hypertension. *Recent Pat Cardiovasc Drug Discov* 1:67–72
- Fang X, Kaduce TL, Weintraub NL, Harmon S, Teesch LM, Morisseau C, Thompson DA, Hammock BD, Spector AA (2001) Pathways of epoxyeicosatrienoic acid metabolism in endothelial cells. Implications for the vascular effects of soluble epoxide hydrolase inhibition. *J Biol Chem* 276:14867–14874. doi:10.1074/jbc.M011761200
- Fillgrove KL, Pakhomova S, Newcomer ME, Armstrong RN (2003) Mechanistic diversity of fosfomycin resistance in pathogenic microorganisms. *J Am Chem Soc* 125:15730–15731. doi:10.1021/ja039307z
- Finley BL, Hammock BD (1988) Increased cholesterol epoxide hydrolyase activity in clofibrate-fed animals. *Biochem Pharmacol* 37:3169–3175. doi:10.1016/0006-2952(88)90316-4
- Fisslthaler B, Popp R, Kiss L, Potente M, Harder DR, Fleming I, Busse R (1999) Cytochrome P450 2C is an EDHF synthase in coronary arteries. *Nature* 401:493–497. doi:10.1038/46816

- Fornage M, Boerwinkle E, Doris PA, Jacobs D, Liu K, Wong ND (2004) Polymorphism of the soluble epoxide hydrolase is associated with coronary artery calcification in African-American subjects: The Coronary Artery Risk Development in Young Adults (CARDIA) study. *Circulation* 109:335–339. doi:10.1161/01.CIR.0000109487.46725.02
- Franken SM, Rozeboom HJ, Kalk KH, Dijkstra BW (1991) Crystal structure of haloalkane dehalogenase: an enzyme to detoxify halogenated alkanes. *EMBO J* 10:1297–1302
- Friedberg T, Becker R, Oesch F, Glatt H (1994a) Studies on the importance of microsomal epoxide hydrolase in the detoxification of arene oxides using the heterologous expression of the enzyme in mammalian cells. *Carcinogenesis* 15:171–175. doi:10.1093/carcin/15.2.171
- Friedberg T, Lollmann B, Becker R, Holler R, Oesch F (1994b) The microsomal epoxide hydrolase has a single membrane signal anchor sequence which is dispensable for the catalytic activity of this protein. *Biochem J* 303(Pt 3):967–972
- Funk CD, Radmark O, Fu JY, Matsumoto T, Jornvall H, Shimizu T, Samuelsson B (1987) Molecular cloning and amino acid sequence of leukotriene A4 hydrolase. *Proc Natl Acad Sci USA* 84:6677–6681. doi:10.1073/pnas.84.19.6677
- Furuta J, Nobeyama Y, Umebayashi Y, Otsuka F, Kikuchi K, Ushijima T (2006) Silencing of Peroxiredoxin 2 and aberrant methylation of 33 CpG islands in putative promoter regions in human malignant melanomas. *Cancer Res* 66:6080–6086. doi:10.1158/0008-5472.CAN-06-0157
- Gaedigk A, Leeder JS, Grant DM (1997) Tissue-specific expression and alternative splicing of human microsomal epoxide hydrolase. *DNA Cell Biol* 16:1257–1266
- Gao J, Lauer FT, Mitchell LA, Burchiel SW (2007) Microsomal epoxide hydrolase is required for 7, 12-dimethylbenz[a]anthracene (DMBA)-induced immunotoxicity in mice. *Toxicol Sci* 98:137–144. doi:10.1093/toxsci/kfm089
- Gomez GA, Morisseau C, Hammock BD, Christianson DW (2004) Structure of human epoxide hydrolase reveals mechanistic inferences on bifunctional catalysis in epoxide and phosphate ester hydrolysis. *Biochemistry* 43:4716–4723. doi:10.1021/bi036189j
- Gonzalez FJ, Kasper CB (1981) Cloning of epoxide hydratase complementary DNA. *J Biol Chem* 256:4697–4700
- Grant DF, Storms DH, Hammock BD (1993) Molecular cloning and expression of murine liver soluble epoxide hydrolase. *J Biol Chem* 268:17628–17633
- Griffin KJ, Gierse J, Krivi G, Fitzpatrick FA (1992) Opioid peptides are substrates for the bifunctional enzyme LTA4 hydrolase/aminopeptidase. *Prostaglandins* 44:251–257. doi:10.1016/0090-6980(92)90018-0
- Gschwendtner A, Ripke S, Freilinger T, Lichtner P, Muller-Myhsok B, Wichmann HE, Meitinger T, Dichgans M (2008) Genetic variation in soluble epoxide hydrolase (EPHX2) is associated with an increased risk of ischemic stroke in white Europeans. *Stroke* 39:1593–1596. doi:10.1161/STROKEAHA.107.502179
- Guengerich FP, Johnson WW, Shimada T, Ueng YF, Yamazaki H, Langouet S (1998) Activation and detoxication of aflatoxin B1. *Mutat Res* 402:121–128. doi:10.1016/S0027-5107(97)00289-3
- Habalova V, Salagovic J, Kalina I, Stubna J (2004) Combined analysis of polymorphisms in glutathione S-transferase M1 and microsomal epoxide hydrolase in lung cancer patients. *Neoplasma* 51:352–357
- Haeggstrom JZ (2004) Leukotriene A4 hydrolase/aminopeptidase, the gatekeeper of chemotactic leukotriene B4 biosynthesis. *J Biol Chem* 279:50639–50642. doi:10.1074/jbc.R400027200
- Haeggstrom JZ, Wetterholm A, Vallee BL, Samuelsson B (1990) Leukotriene A4 hydrolase: an epoxide hydrolase with peptidase activity. *Biochem Biophys Res Commun* 173:431–437. doi:10.1016/S0006-291X(05)81076-9
- Haeggstrom JZ, Kull F, Rudberg PC, Tholander F, Thunissen MM (2002) Leukotriene A4 hydrolase. *Prostaglandins Other Lipid Mediat* 68–69:495–510. doi:10.1016/S0090-6980(02)00051-5
- Haeggstrom JZ, Tholander F, Wetterholm A (2007) Structure and catalytic mechanisms of leukotriene A4 hydrolase. *Prostaglandins Other Lipid Mediat* 83:198–202. doi:10.1016/j.prostaglandins.2007.01.006
- Harris TR, Aronov PA, Jones PD, Tanaka H, Arand M, Hammock BD (2008) Identification of two epoxide hydrolases in *Caenorhabditis elegans* that metabolize mammalian lipid signaling molecules. *Arch Biochem Biophys*
- Hassett C, Turnblom SM, DeAngelo A, Omiecinski CJ (1989) Rabbit microsomal epoxide hydrolase: isolation and characterization of the xenobiotic metabolizing enzyme cDNA. *Arch Biochem Biophys* 271:380–389. doi:10.1016/0003-9861(89)90287-7
- Hassett C, Aicher L, Sidhu JS, Omiecinski CJ (1994) Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants. *Hum Mol Genet* 3:421–428. doi:10.1093/hmg/3.3.421
- Hassett C, Lin J, Carty CL, Laurenzana EM, Omiecinski CJ (1997) Human hepatic microsomal epoxide hydrolase: comparative analysis of polymorphic expression. *Arch Biochem Biophys* 337:275–283. doi:10.1006/abbi.1996.9794
- Hengstler JG, Arand M, Herrero ME, Oesch F (1998) Polymorphisms of *N*-acetyltransferases, glutathione S-transferases, microsomal epoxide hydrolase and sulfotransferases: influence on cancer susceptibility. *Recent Results Cancer Res* 154:47–85
- Hennebold JD, Mah K, Perez W, Vance JE, Stouffer RL, Morisseau C, Hammock BD, Adashi EY (2005) Identification and characterization of an ovary-selective isoform of epoxide hydrolase. *Biol Reprod* 72:968–975. doi:10.1095/biolreprod.104.035899
- Herrero ME, Arand M, Hengstler JG, Oesch F (1997) Recombinant expression of human microsomal epoxide hydrolase protects V79 Chinese hamster cells from styrene oxide—but not from ethylene oxide-induced DNA strand breaks. *Environ Mol Mutagen* 30:429–439. doi:10.1002/(SICI)1098-2280(1997)30:4<429::AID-EM8>3.0.CO;2-D
- Holder G, Yagi H, Dansette P, Jerina DM, Levin W, Lu AY, Conney AH (1974) Effects of inducers and epoxide hydrolase on the metabolism of benzo[a]pyrene by liver microsomes and a reconstituted system: analysis by high pressure liquid chromatography. *Proc Natl Acad Sci USA* 71:4356–4360. doi:10.1073/pnas.71.11.4356
- Holler R, Arand M, Mecky A, Oesch F, Friedberg T (1997) The membrane anchor of microsomal epoxide hydrolase from human, rat, and rabbit displays an unexpected membrane topology. *Biochem Biophys Res Commun* 236:754–759. doi:10.1006/bbrc.1997.7044
- Holmquist M (2000) Alpha/beta-hydrolase fold enzymes: structures, functions and mechanisms. *Curr Protein Pept Sci* 1:209–235. doi:10.2174/1389203003381405
- Honscha W, Platte HD, Oesch F, Friedberg T (1995) Relationship between the microsomal epoxide hydrolase and the hepatocellular transport of bile acids and xenobiotics. *Biochem J* 311(Pt 3):975–979
- Hu S, Kim HS (1993) Activation of K⁺ channel in vascular smooth muscles by cytochrome P450 metabolites of arachidonic acid. *Eur J Pharmacol* 230:215–221. doi:10.1016/0014-2999(93)90805-R
- Imig JD (2005) Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases. *Am J Physiol Renal Physiol* 289:F496–F503. doi:10.1152/ajprenal.00350.2004
- Imig JD, Navar LG, Roman RJ, Reddy KK, Falck JR (1996) Actions of epoxygenase metabolites on the preglomerular vasculature. *J Am Soc Nephrol* 7:2364–2370
- Imig JD, Zhao X, Capdevila JH, Morisseau C, Hammock BD (2002) Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. *Hypertension* 39:690–694. doi:10.1161/hy0202.103788

- Inceoglu B, Jinks SL, Schmelzer KR, Waite T, Kim IH, Hammock BD (2006) Inhibition of soluble epoxide hydrolase reduces LPS-induced thermal hyperalgesia and mechanical allodynia in a rat model of inflammatory pain. *Life Sci* 79:2311–2319. doi:10.1016/j.lfs.2006.07.031
- Janssen DB, Pries F, van der Ploeg J, Kazemier B, Terpstra P, Witholt B (1989) Cloning of 1, 2-dichloroethane degradation genes of *Xanthobacter autotrophicus* GJ10 and expression and sequencing of the dhla gene. *J Bacteriol* 171:6791–6799
- Johansson C, Stark A, Sandberg M, Ek B, Rask L, Meijer J (1995) Tissue specific basal expression of soluble murine epoxide hydrolase and effects of clofibrate on the mRNA levels in extrahepatic tissues and liver. *Arch Toxicol* 70:61–63. doi:10.1007/s002040050250
- Johansson P, Unge T, Cronin A, Arand M, Bergfors T, Jones TA, Mowbray SL (2005) Structure of an atypical epoxide hydrolase from *Mycobacterium tuberculosis* gives insights into its function. *J Mol Biol* 351:1048–1056. doi:10.1016/j.jmb.2005.06.055
- Kaneko-Ishino T, Kuroiwa Y, Miyoshi N, Kohda T, Suzuki R, Yokoyama M, Viville S, Barton SC, Ishino F, Surani MA (1995) Peg1/Mest imprinted gene on chromosome 6 identified by cDNA subtraction hybridization. *Nat Genet* 11:52–59. doi:10.1038/ng0995-52
- Kelly EJ, Erickson KE, Sengstag C, Eaton DL (2002) Expression of human microsomal epoxide hydrolase in *Saccharomyces cerevisiae* reveals a functional role in aflatoxin B1 detoxification. *Toxicol Sci* 65:35–42. doi:10.1093/toxsci/65.1.35
- Kim IH, Morisseau C, Watanabe T, Hammock BD (2004) Design, synthesis, and biological activity of 1, 3-disubstituted ureas as potent inhibitors of the soluble epoxide hydrolase of increased water solubility. *J Med Chem* 47:2110–2122. doi:10.1021/jm030514j
- Kim IH, Nishi K, Tsai HJ, Bradford T, Koda Y, Watanabe T, Morisseau C, Blanchfield J, Toth I, Hammock BD (2007) Design of bioavailable derivatives of 12-(3-adamantan-1-yl-ureido)dodecanoic acid, a potent inhibitor of the soluble epoxide hydrolase. *Bioorg Med Chem* 15:312–323. doi:10.1016/j.bmc.2006.09.057
- Kiyohara C, Yoshimasu K, Takayama K, Nakanishi Y (2006) EPHX1 polymorphisms and the risk of lung cancer: a HuGe review. *Epidemiology* 17:89–99. doi:10.1097/01.ede.0000187627.70026.23
- Knehr M, Thomas H, Arand M, Gebel T, Zeller HD, Oesch F (1993) Isolation and characterization of a cDNA encoding rat liver cytosolic epoxide hydrolase and its functional expression in *Escherichia coli*. *J Biol Chem* 268:17623–17627
- Kobayashi S, Kohda T, Miyoshi N, Kuroiwa Y, Aisaka K, Tsutsumi O, Kaneko-Ishino T, Ishino F (1997) Human PEG1/MEST, an imprinted gene on chromosome 7. *Hum Mol Genet* 6:781–786. doi:10.1093/hmg/6.5.781
- Koerner IP, Jacks R, DeBarber AE, Koop D, Mao P, Grant DF, Alkayed NJ (2007) Polymorphisms in the human soluble epoxide hydrolase gene EPHX2 linked to neuronal survival after ischemic injury. *J Neurosci* 27:4642–4649. doi:10.1523/JNEUROSCI.0056-07.2007
- Koonin EV, Tatusov RL (1994) Computer analysis of bacterial haloacid dehalogenases defines a large superfamily of hydrolases with diverse specificity. Application of an iterative approach to database search. *J Mol Biol* 244:125–132. doi:10.1006/jmbi.1994.1711
- Krause RJ, Sharer JE, Elfarra AA (1997) Epoxide hydrolase-dependent metabolism of butadiene monoxide to 3-butene-1, 2-diol in mouse, rat, and human liver. *Drug Metab Dispos* 25:1013–1015
- Kwak MK, Itoh K, Yamamoto M, Sutter TR, Kensler TW (2001) Role of transcription factor Nrf2 in the induction of hepatic phase 2 and antioxidative enzymes in vivo by the cancer chemoprotective agent, 3H-1, 2-dimethiole-3-thione. *Mol Med* 7:135–145
- Lacourciere GM, Armstrong RN (1994) Microsomal and soluble epoxide hydrolases are members of the same family of C-X bond hydrolase enzymes. *Chem Res Toxicol* 7:121–124. doi:10.1021/tx00038a001
- Lacourciere GM, Vakharia VN, Tan CP, Morris DI, Edwards GH, Moos M, Armstrong RN (1993) Interaction of hepatic microsomal epoxide hydrolase derived from a recombinant baculovirus expression system with an azarene oxide and an aziridine substrate analogue. *Biochemistry* 32:2610–2616. doi:10.1021/bi00061a019
- Lahiri SD, Zhang G, Dai J, Dunaway-Mariano D, Allen KN (2004) Analysis of the substrate specificity loop of the HAD superfamily cap domain. *Biochemistry* 43:2812–2820. doi:10.1021/bi0356810
- Lahiri SD, Zhang G, Dunaway-Mariano D, Allen KN (2006) Diversification of function in the haloacid dehalogenase enzyme superfamily: the role of the cap domain in hydrolytic phosphorus-carbon bond cleavage. *Bioorg Chem* 34:394–409. doi:10.1016/j.bioorg.2006.09.007
- Laneville O, Corey EJ, Couture R, Pace-Asciak CR (1991) Hepoxilin A3 (HxA3) is formed by the rat aorta and is metabolized into HxA3-C, a glutathione conjugate. *Biochim Biophys Acta* 1084:60–68
- Laughlin LT, Tzeng HF, Lin S, Armstrong RN (1998) Mechanism of microsomal epoxide hydrolase. Semifunctional site-specific mutants affecting the alkylation half-reaction. *Biochemistry* 37:2897–2904. doi:10.1021/bi972737f
- Lee WJ, Brennan P, Boffetta P, London SJ, Benhamou S, Rannug A, To-Figueras J, Ingelman-Sundberg M, Shields P, Gaspari L, Taioli E (2002) Microsomal epoxide hydrolase polymorphisms and lung cancer risk: a quantitative review. *Biomarkers* 7:230–241. doi:10.1080/13547500210121882
- Lee CR, North KE, Bray MS, Fornage M, Seubert JM, Newman JW, Hammock BD, Couper DJ, Heiss G, Zeldin DC (2006) Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) study. *Hum Mol Genet* 15:1640–1649. doi:10.1093/hmg/ddl085
- Lefebvre L, Viville S, Barton SC, Ishino F, Surani MA (1997) Genomic structure and parent-of-origin-specific methylation of Peg1. *Hum Mol Genet* 6:1907–1915. doi:10.1093/hmg/6.11.1907
- Li PL, Campbell WB (1997) Epoxyeicosatrienoic acids activate K⁺ channels in coronary smooth muscle through a guanine nucleotide binding protein. *Circ Res* 80:877–884
- Li J, Carroll MA, Chander PN, Falck JR, Sangras B, Stier CT (2008) Soluble epoxide hydrolase inhibitor, AUDA, prevents early salt-sensitive hypertension. *Front Biosci* 13:3480–3487. doi:10.2741/2942
- Lin TS, Huang HH, Fan YH, Chiou SH, Chow KC (2007) Genetic polymorphism and gene expression of microsomal epoxide hydrolase in non-small cell lung cancer. *Oncol Rep* 17:565–572
- Liu Y, Zhang Y, Schmelzer K, Lee TS, Fang X, Zhu Y, Spector AA, Gill S, Morisseau C, Hammock BD, Shyy JY (2005) The anti-inflammatory effect of laminar flow: the role of PPARgamma, epoxyeicosatrienoic acids, and soluble epoxide hydrolase. *Proc Natl Acad Sci USA* 102:16747–16752. doi:10.1073/pnas.0508081102
- Liu M, Sun A, Shin EJ, Liu X, Kim SG, Runyons CR, Markesbery W, Kim HC, Bing G (2006) Expression of microsomal epoxide hydrolase is elevated in Alzheimer's hippocampus and induced by exogenous beta-amyloid and trimethyl-tin. *Eur J Neurosci* 23:2027–2034. doi:10.1111/j.1460-9568.2006.04724.x
- Liu M, Hunter R, Nguyen XV, Kim HC, Bing G (2008) Microsomal epoxide hydrolase deletion enhances tyrosine hydroxylase phosphorylation in mice after MPTP treatment. *J Neurosci Res* 86:2792–2801
- Lundgren B, Meijer J, DePierre JW (1987) Induction of cytosolic and microsomal epoxide hydrolases and proliferation of peroxisomes and mitochondria in mouse liver after dietary exposure to p-chlorophenoxyacetic acid, 2, 4-dichlorophenoxyacetic acid and 2, 4,

- 5-trichlorophenoxyacetic acid. *Biochem Pharmacol* 36:815–821. doi:10.1016/0006-2952(87)90169-9
- Luo B, Norris C, Bolstad ES, Knecht DA, Grant DF (2008) Protein quaternary structure and expression levels contribute to peroxisomal-targeting-sequence-1-mediated peroxisomal import of human soluble epoxide hydrolase. *J Mol Biol* 380:31–41. doi:10.1016/j.jmb.2008.04.064
- Luria A, Weldon SM, Kabcenell AK, Ingraham RH, Matera D, Jiang H, Gill R, Morisseau C, Newman JW, Hammock BD (2007) Compensatory mechanism for homeostatic blood pressure regulation in Ephx2 gene-disrupted mice. *J Biol Chem* 282:2891–2898. doi:10.1074/jbc.M608057200
- McGee J, Fitzpatrick F (1985) Enzymatic hydration of leukotriene A4. Purification and characterization of a novel epoxide hydrolase from human erythrocytes. *J Biol Chem* 260:12832–12837
- McGlynn KA, Rosvold EA, Lustbader ED, Hu Y, Clapper ML, Zhou T, Wild CP, Xia XL, Baffoe-Bonnie A, Ofori-Adjei D et al (1995) Susceptibility to hepatocellular carcinoma is associated with genetic variation in the enzymatic detoxification of aflatoxin B1. *Proc Natl Acad Sci USA* 92:2384–2387. doi:10.1073/pnas.92.6.2384
- McGlynn KA, Hunter K, LeVoyer T, Roush J, Wise P, Michielli RA, Shen FM, Evans AA, London WT, Buetow KH (2003) Susceptibility to aflatoxin B1-related primary hepatocellular carcinoma in mice and humans. *Cancer Res* 63:4594–4601
- Merrell MD, Augustine LM, Slitt AL, Cherrington NJ (2008) Induction of drug metabolism enzymes and transporters by oltipraz in rats. *J Biochem Mol Toxicol* 22:128–135. doi:10.1002/jbt.20225
- Michaelis UR, Fisslthaler B, Barbosa-Sicard E, Falck JR, Fleming I, Busse R (2005) Cytochrome P450 epoxygenases 2C8 and 2C9 are implicated in hypoxia-induced endothelial cell migration and angiogenesis. *J Cell Sci* 118:5489–5498. doi:10.1242/jcs.02674
- Minami M, Ohishi N, Mutoh H, Izumi T, Bito H, Wada H, Seyama Y, Toh H, Shimizu T (1990) Leukotriene A4 hydrolase is a zinc-containing aminopeptidase. *Biochem Biophys Res Commun* 173:620–626. doi:10.1016/S0006-291X(05)80080-4
- Mittal RD, Srivastava DL (2007) Cytochrome P4501A1 and microsomal epoxide hydrolase gene polymorphisms: gene–environment interaction and risk of prostate cancer. *DNA Cell Biol* 26:791–798. doi:10.1089/dna.2007.0630
- Miyata M, Kudo G, Lee YH, Yang TJ, Gelboin HV, Fernandez-Salguero P, Kimura S, Gonzalez FJ (1999) Targeted disruption of the microsomal epoxide hydrolase gene. Microsomal epoxide hydrolase is required for the carcinogenic activity of 7, 12-dimethylbenz[a]anthracene. *J Biol Chem* 274:23963–23968. doi:10.1074/jbc.274.34.23963
- Moghaddam M, Motoba K, Borhan B, Pinot F, Hammock BD (1996) Novel metabolic pathways for linoleic and arachidonic acid metabolism. *Biochim Biophys Acta* 1290:327–339
- Monti J, Fischer J, Paskas S, Heinig M, Schulz H, Gosele C, Heuser A, Fischer R, Schmidt C, Schirdewan A, Gross V, Hummel O, Maatz H, Patone G, Saar K, Vingron M, Weldon SM, Lindpaintner K, Hammock BD, Rohde K, Dietz R, Cook SA, Schunck WH, Luft FC, Hubner N (2008) Soluble epoxide hydrolase is a susceptibility factor for heart failure in a rat model of human disease. *Nat Genet* 40:529–537. doi:10.1038/ng.129
- Morais MC, Zhang W, Baker AS, Zhang G, Dunaway-Mariano D, Allen KN (2000) The crystal structure of bacillus cereus phosphonoacetaldehyde hydrolase: insight into catalysis of phosphorus bond cleavage and catalytic diversification within the HAD enzyme superfamily. *Biochemistry* 39:10385–10396. doi:10.1021/bi001171j
- Morisseau C, Hammock BD (2005) Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles. *Annu Rev Pharmacol Toxicol* 45:311–333. doi:10.1146/annurev.pharmtox.45.120403.095920
- Morisseau C, Du G, Newman JW, Hammock BD (1998) Mechanism of mammalian soluble epoxide hydrolase inhibition by chalcone oxide derivatives. *Arch Biochem Biophys* 356:214–228. doi:10.1006/abbi.1998.0756
- Morisseau C, Newman JW, Dowdy DL, Goodrow MH, Hammock BD (2001) Inhibition of microsomal epoxide hydrolases by ureas, amides, and amines. *Chem Res Toxicol* 14:409–415. doi:10.1021/tx000173z
- Morisseau C, Goodrow MH, Newman JW, Wheelock CE, Dowdy DL, Hammock BD (2002) Structural refinement of inhibitors of urea-based soluble epoxide hydrolases. *Biochem Pharmacol* 63:1599–1608. doi:10.1016/S0006-2952(02)00952-8
- Morisseau C, Newman JW, Tsai HJ, Baecker PA, Hammock BD (2006) Peptidyl-urea based inhibitors of soluble epoxide hydrolases. *Bioorg Med Chem Lett* 16:5439–5444. doi:10.1016/j.bmcl.2006.07.073
- Morisseau C, Newman JW, Wheelock CE, Hill Iii T, Morin D, Buckpitt AR, Hammock BD (2008) Development of metabolically stable inhibitors of Mammalian microsomal epoxide hydrolase. *Chem Res Toxicol* 21:951–957. doi:10.1021/tx700446u
- Mowbray SL, Elfstrom LT, Ahlgren KM, Andersson CE, Widersten M (2006) X-ray structure of potato epoxide hydrolase sheds light on substrate specificity in plant enzymes. *Protein Sci* 15:1628–1637. doi:10.1110/ps.051792106
- Mrsny RJ, Gewirtz AT, Siccardi D, Savidge T, Hurley BP, Madara JL, McCormick BA (2004) Identification of hepoxilin A3 in inflammatory events: a required role in neutrophil migration across intestinal epithelia. *Proc Natl Acad Sci USA* 101:7421–7426. doi:10.1073/pnas.0400832101
- Mullen RT, Trelease RN, Duerk H, Arand M, Hammock BD, Oesch F, Grant DF (1999) Differential subcellular localization of endogenous and transfected soluble epoxide hydrolase in mammalian cells: evidence for isozyme variants. *FEBS Lett* 445:301–305. doi:10.1016/S0014-5793(99)00142-8
- Muller F, Arand M, Frank H, Seidel A, Hinz W, Winkler L, Hanel K, Blee E, Beetham JK, Hammock BD, Oesch F (1997) Visualization of a covalent intermediate between microsomal epoxide hydrolase, but not cholesterol epoxide hydrolase, and their substrates. *Eur J Biochem* 245:490–496. doi:10.1111/j.1432-1033.1997.00490.x
- Nakanishi H, Suda T, Katoh M, Watanabe A, Igishi T, Kodani M, Matsumoto S, Nakamoto M, Shigeoka Y, Okabe T, Oshimura M, Shimizu E (2004) Loss of imprinting of PEG1/MEST in lung cancer cell lines. *Oncol Rep* 12:1273–1278
- Nardini M, Ridder IS, Rozeboom HJ, Kalk KH, Rink R, Janssen DB, Dijkstra BW (1999) The x-ray structure of epoxide hydrolase from *Agrobacterium radiobacter* AD1. An enzyme to detoxify harmful epoxides. *J Biol Chem* 274:14579–14586. doi:10.1074/jbc.274.21.14579
- Newman JW, Morisseau C, Harris TR, Hammock BD (2003) The soluble epoxide hydrolase encoded by EPXH2 is a bifunctional enzyme with novel lipid phosphate phosphatase activity. *Proc Natl Acad Sci USA* 100:1558–1563. doi:10.1073/pnas.0437724100
- Newman JW, Morisseau C, Hammock BD (2005) Epoxide hydrolases: their roles and interactions with lipid metabolism. *Prog Lipid Res* 44:1–51. doi:10.1016/j.plipres.2004.10.001
- Nigam S, Zafiriou MP, Deva R, Ciccoli R, Roux-Van der Merwe R (2007) Structure, biochemistry and biology of hepoxilins: an update. *FEBS J* 274:3503–3512. doi:10.1111/j.1742-4658.2007.05910.x
- Nikonova L, Koza RA, Mendoza T, Chao PM, Curley JP, Kozak LP (2008) Mesoderm-specific transcript is associated with fat mass expansion in response to a positive energy balance. *FASEB J* 22:3925–3937. doi:10.1096/fj.08-108266
- Oesch F (1973) Mammalian epoxide hydrolases: inducible enzymes catalysing the inactivation of carcinogenic and cytotoxic

- metabolites derived from aromatic and olefinic compounds. *Xenobiotica* 3:305–340
- Oesch F (1974) Purification and specificity of a human microsomal epoxide hydratase. *Biochem J* 139:77–88
- Oesch F, Timms CW, Walker CH, Guenther TM, Sparrow A, Watabe T, Wolf CR (1984) Existence of multiple forms of microsomal epoxide hydrolases with radically different substrate specificities. *Carcinogenesis* 5:7–9. doi:10.1093/carcin/5.1.7
- Oesch F, Schladt L, Hartmann R, Timms C, Worner W (1986) Rat cytosolic epoxide hydrolase. *Adv Exp Med Biol* 197:195–201
- Oesch F, Herrero ME, Hengstler JG, Lohmann M, Arand M (2000) Metabolic detoxification: implications for thresholds. *Toxicol Pathol* 28:382–387. doi:10.1177/019262330002800305
- Ohtoshi K, Kaneto H, Node K, Nakamura Y, Shiraiwa T, Matsuhiya M, Yamasaki Y (2005) Association of soluble epoxide hydrolase gene polymorphism with insulin resistance in type 2 diabetic patients. *Biochem Biophys Res Commun* 331:347–350. doi:10.1016/j.bbrc.2005.03.171
- Oliw EH, Guengerich FP, Oates JA (1982) Oxygenation of arachidonic acid by hepatic monooxygenases. Isolation and metabolism of four epoxide intermediates. *J Biol Chem* 257:3771–3781
- Omiencinski CJ, Hassett C, Hosagrahara V (2000) Epoxide hydrolase—polymorphism and role in toxicology. *Toxicol Lett* 112–113:365–370. doi:10.1016/S0378-4274(99)00235-0
- Pace-Asciak CR, Lee WS (1989) Purification of hepxilin epoxide hydrolase from rat liver. *J Biol Chem* 264:9310–9313
- Pace-Asciak CR, Martin JM (1984) Hepoxilin, a new family of insulin secretagogues formed by intact rat pancreatic islets. *Prostaglandins Leukot Med* 16:173–180. doi:10.1016/0262-1746(84)90069-6
- Pace-Asciak CR, Laneuville O, Su WG, Corey EJ, Gurevich N, Wu P, Carlen PL (1990) A glutathione conjugate of hepxilin A3: formation and action in the rat central nervous system. *Proc Natl Acad Sci USA* 87:3037–3041. doi:10.1073/pnas.87.8.3037
- Pace-Asciak CR, Reynaud D, Demin PM (1995) Hepoxilins: a review on their enzymatic formation, metabolism and chemical synthesis. *Lipids* 30:107–114. doi:10.1007/BF02538262
- Papadopoulos D, Seidegard J, Georgellis A, Rydstrom J (1985) Subcellular distribution, catalytic properties and partial purification of epoxide hydrolase in the human adrenal gland. *Chem Biol Interact* 55:249–260. doi:10.1016/S0009-2797(85)80133-2
- Pedersen IS, Dervan PA, Broderick D, Harrison M, Miller N, Delany E, O'Shea D, Costello P, McGoldrick A, Keating G, Tobin B, Gorey T, McCann A (1999) Frequent loss of imprinting of PEG1/MEST in invasive breast cancer. *Cancer Res* 59:5449–5451
- Pinot F, Grant DF, Beetham JK, Parker AG, Borhan B, Landt S, Jones AD, Hammock BD (1995) Molecular and biochemical evidence for the involvement of the Asp-333-His-523 pair in the catalytic mechanism of soluble epoxide hydrolase. *J Biol Chem* 270:7968–7974. doi:10.1074/jbc.270.14.7968
- Pomposiello SI, Quilley J, Carroll MA, Falck JR, McGiff JC (2003) 5, 6-Epoxyeicosatrienoic acid mediates the enhanced renal vasodilation to arachidonic acid in the SHR. *Hypertension* 42:548–554. doi:10.1161/01.HYP.0000090095.87899.36
- Potente M, Fisslthaler B, Busse R, Fleming I (2003) 11, 12-Epoxyeicosatrienoic acid-induced inhibition of FOXO factors promotes endothelial proliferation by down-regulating p27Kip1. *J Biol Chem* 278:29619–29625. doi:10.1074/jbc.M305385200
- Prestwich GD, Lucarelli I, Park SK, Loury DN, Moody DE, Hammock BD (1985) Cyclopropyl oxiranes: reversible inhibitors of cytosolic and microsomal epoxide hydrolases. *Arch Biochem Biophys* 237:361–372. doi:10.1016/0003-9861(85)90288-7
- Przybyla-Zawislak BD, Srivastava PK, Vazquez-Matias J, Mohrenweiser HW, Maxwell JE, Hammock BD, Bradbury JA, Enayetallah AE, Zeldin DC, Grant DF (2003) Polymorphisms in human soluble epoxide hydrolase. *Mol Pharmacol* 64:482–490. doi:10.1124/mol.64.2.482
- Raaka S, Hassett C, Omiencinski CJ (1998) Human microsomal epoxide hydrolase: 5'-flanking region genetic polymorphisms. *Carcinogenesis* 19:387–393. doi:10.1093/carcin/19.3.387
- Radmark O, Shimizu T, Jornvall H, Samuelsson B (1984) Leukotriene A4 hydrolase in human leukocytes. Purification and properties. *J Biol Chem* 259:12339–12345
- Rappaport SM, Yeowell-O'Connell K, Bodell W, Yager JW, Symanski E (1996) An investigation of multiple biomarkers among workers exposed to styrene and styrene-7, 8-oxide. *Cancer Res* 56:5410–5416
- Recio L, Bauer A, Faiola B (2005) Use of genetically modified mouse models to assess pathways of benzene-induced bone marrow cytotoxicity and genotoxicity. *Chem Biol Interact* 153–154:159–164. doi:10.1016/j.cbi.2005.03.020
- Reddy BS, Wynder EL (1977) Metabolic epidemiology of colon cancer. Fecal bile acids and neutral sterols in colon cancer patients and patients with adenomatous polyps. *Cancer* 39:2533–2539. doi:10.1002/1097-0142(197706)39:6<2533::AID-CNCR2820390634>3.0.CO;2-X
- Reynaud D, Demin PM, Sutherland M, Nigam S, Pace-Asciak CR (1999) Hepoxilin signaling in intact human neutrophils: biphasic elevation of intracellular calcium by unesterified hepxilin A3. *FEBS Lett* 446:236–238. doi:10.1016/S0014-5793(99)00225-2
- Rigsby RE, Fillgrove KL, Beihoffer LA, Armstrong RN (2005) Fosfomycin resistance proteins: a nexus of glutathione transferases and epoxide hydrolases in a metalloenzyme superfamily. *Methods Enzymol* 401:367–379. doi:10.1016/S0076-6879(05)01023-2
- Rimner A, Al Makkessi S, Sweidan H, Wischhusen J, Rabenstein B, Shatat K, Mayer P, Spyridopoulos I (2005) Relevance and mechanism of oxysterol stereospecificity in coronary artery disease. *Free Radic Biol Med* 38:535–544. doi:10.1016/j.freeradbiomed.2004.11.016
- Ryan L, O'Callaghan YC, O'Brien NM (2004) Comparison of the apoptotic processes induced by the oxysterols 7beta-hydroxycholesterol and cholesterol-5beta, 6beta-epoxide. *Cell Biol Toxicol* 20:313–323. doi:10.1007/s10565-004-5066-7
- Saito S, Iida A, Sekine A, Eguchi C, Miura Y, Nakamura Y (2001) Seventy genetic variations in human microsomal and soluble epoxide hydrolase genes (EPHX1 and EPHX2) in the Japanese population. *J Hum Genet* 46:325–329. doi:10.1007/s100380170067
- Sandberg M, Meijer J (1996) Structural characterization of the human soluble epoxide hydrolase gene (EPHX2). *Biochem Biophys Res Commun* 221:333–339. doi:10.1006/bbrc.1996.0596
- Sandberg M, Hassett C, Adman ET, Meijer J, Omiencinski CJ (2000) Identification and functional characterization of human soluble epoxide hydrolase genetic polymorphisms. *J Biol Chem* 275:28873–28881. doi:10.1074/jbc.M001153200
- Sato K, Emi M, Ezura Y, Fujita Y, Takada D, Ishigami T, Umemura S, Xin Y, Wu LL, Larrinaga-Shum S, Stephenson SH, Hunt SC, Hopkins PN (2004) Soluble epoxide hydrolase variant (Glu287Arg) modifies plasma total cholesterol and triglyceride phenotype in familial hypercholesterolemia: intrafamilial association study in an eight-generation hyperlipidemic kindred. *J Hum Genet* 49:29–34. doi:10.1007/s10038-003-0103-6
- Schmelzer KR, Kubala L, Newman JW, Kim IH, Eiserich JP, Hammock BD (2005) Soluble epoxide hydrolase is a therapeutic target for acute inflammation. *Proc Natl Acad Sci USA* 102:9772–9777. doi:10.1073/pnas.0503279102
- Schmelzer KR, Inceoglu B, Kubala L, Kim IH, Jinks SL, Eiserich JP, Hammock BD (2006) Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors. *Proc Natl Acad Sci USA* 103:13646–13651. doi:10.1073/pnas.0605908103
- Selengut JD (2001) MDP-1 is a new and distinct member of the haloacid dehalogenase family of aspartate-dependent phosphohydrolases. *Biochemistry* 40:12704–12711. doi:10.1021/bi011405e

- Sevanian A, Peterson AR (1984) Cholesterol epoxide is a direct-acting mutagen. *Proc Natl Acad Sci USA* 81:4198–4202. doi:10.1073/pnas.81.13.4198
- Sevanian A, Peterson AR (1986) The cytotoxic and mutagenic properties of cholesterol oxidation products. *Food Chem Toxicol* 24:1103–1110. doi:10.1016/0278-6915(86)90295-4
- Shimada T (2006) Xenobiotic-metabolizing enzymes involved in activation and detoxification of carcinogenic polycyclic aromatic hydrocarbons. *Drug Metab Pharmacokinet* 21:257–276. doi:10.2133/dmpk.21.257
- Shkolnik K, Ben-Dor S, Galiani D, Hourvitz A, Dekel N (2007) A novel ovary-specific and ovulation-associated variant of epoxide hydrolase 2. *FEBS Lett* 581:4891–4898. doi:10.1016/j.febslet.2007.09.016
- Shou M, Gonzalez FJ, Gelboin HV (1996) Stereoselective epoxidation and hydration at the K-region of polycyclic aromatic hydrocarbons by cDNA-expressed cytochromes P450 1A1, 1A2, and epoxide hydrolase. *Biochemistry* 35:15807–15813. doi:10.1021/bi962042z
- Sinal CJ, Miyata M, Tohkin M, Nagata K, Bend JR, Gonzalez FJ (2000) Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation. *J Biol Chem* 275:40504–40510. doi:10.1074/jbc.M008106200
- Smit MS (2004) Fungal epoxide hydrolases: new landmarks in sequence-activity space. *Trends Biotechnol* 22:123–129. doi:10.1016/j.tibtech.2004.01.012
- Smith CA, Harrison DJ (1997) Association between polymorphism in gene for microsomal epoxide hydrolase and susceptibility to emphysema. *Lancet* 350:630–633. doi:10.1016/S0140-6736(96)08061-0
- Smith KR, Pinkerton KE, Watanabe T, Pedersen TL, Ma SJ, Hammock BD (2005) Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor. *Proc Natl Acad Sci USA* 102:2186–2191. doi:10.1073/pnas.0409591102
- Snider NT, Kornilov AM, Kent UM, Hollenberg PF (2007) Anandamide metabolism by human liver and kidney microsomal cytochrome p450 enzymes to form hydroxyeicosatetraenoic and epoxyeicosatrienoic acid ethanalamides. *J Pharmacol Exp Ther* 321:590–597. doi:10.1124/jpet.107.119321
- Snyder R, Chepiga T, Yang CS, Thomas H, Platt K, Oesch F (1993) Benzene metabolism by reconstituted cytochromes P450 2B1 and 2E1 and its modulation by cytochrome b5, microsomal epoxide hydrolase, and glutathione transferases: evidence for an important role of microsomal epoxide hydrolase in the formation of hydroquinone. *Toxicol Appl Pharmacol* 122:172–181. doi:10.1006/taap.1993.1185
- Spector AA, Norris AW (2007) Action of epoxyeicosatrienoic acids on cellular function. *Am J Physiol Cell Physiol* 292:C996–C1012. doi:10.1152/ajpcell.00402.2006
- Srivastava PK, Sharma VK, Kalonia DS, Grant DF (2004) Polymorphisms in human soluble epoxide hydrolase: effects on enzyme activity, enzyme stability, and quaternary structure. *Arch Biochem Biophys* 427:164–169. doi:10.1016/j.abb.2004.05.003
- Stansberg C, Vik-Mo AO, Holdhus R, Breilid H, Srebro B, Petersen K, Jorgensen HA, Jonassen I, Steen VM (2007) Gene expression profiles in rat brain disclose CNS signature genes and regional patterns of functional specialisation. *BMC Genomics* 8:94. doi:10.1186/1471-2164-8-94
- Summerer S, Hanano A, Utsumi S, Arand M, Schuber F, Blee E (2002) Stereochemical features of the hydrolysis of 9, 10-epoxystearic acid catalysed by plant and mammalian epoxide hydrolases. *Biochem J* 366:471–480. doi:10.1042/BJ20011778
- Summer SJ, Fennell TR (1994) Review of the metabolic fate of styrene. *Crit Rev Toxicol* 24(1):S11–S33. doi:10.3109/10408449409020138
- Sun J, Sui X, Bradbury JA, Zeldin DC, Conte MS, Liao JK (2002) Inhibition of vascular smooth muscle cell migration by cytochrome p450 epoxygenase-derived eicosanoids. *Circ Res* 90:1020–1027. doi:10.1161/01.RES.0000017727.35930.33
- Sun Z, Sood S, Li N, Ramji D, Yang P, Newman RA, Yang CS, Chen X (2006) Involvement of the 5-lipoxygenase/leukotriene A4 hydrolase pathway in 7, 12-dimethylbenz[a]anthracene (DMBA)-induced oral carcinogenesis in hamster cheek pouch, and inhibition of carcinogenesis by its inhibitors. *Carcinogenesis* 27:1902–1908. doi:10.1093/carcin/bgl039
- Sura P, Sura R, Enayetallah AE, Grant DF (2008) Distribution and expression of soluble epoxide hydrolase in human brain. *J Histochem Cytochem* 56:551–559. doi:10.1369/jhc.2008.950659
- Terashvili M, Tseng LF, Wu HE, Narayanan J, Hart LM, Falck JR, Pratt PF, Harder DR (2008) Antinociception produced by 14,15-epoxyeicosatrienoic acid is mediated by the activation of {beta}-endorphin and Met-enkephalin in the rat ventrolateral periaqueductal gray. *J Pharmacol Exp Ther* 326:614–622
- Thunnissen MM, Nordlund P, Haeggstrom JZ (2001) Crystal structure of human leukotriene A(4) hydrolase, a bifunctional enzyme in inflammation. *Nat Struct Biol* 8:131–135. doi:10.1038/84117
- Toulza E, Mattiuzzo NR, Galliano MF, Jonca N, Dossat C, Jacob D, de Daruvar A, Wincker P, Serre G, Guerrin M (2007) Large-scale identification of human genes implicated in epidermal barrier function. *Genome Biol* 8:R107. doi:10.1186/gb-2007-8-6-r107
- Tran KL, Aronov PA, Tanaka H, Newman JW, Hammock BD, Morisseau C (2005) Lipid sulfates and sulfonates are allosteric competitive inhibitors of the N-terminal phosphatase activity of the mammalian soluble epoxide hydrolase. *Biochemistry* 44:12179–12187. doi:10.1021/bi050842g
- Tranah GJ, Chan AT, Giovannucci E, Ma J, Fuchs C, Hunter DJ (2005) Epoxide hydrolase and CYP2C9 polymorphisms, cigarette smoking, and risk of colorectal carcinoma in the Nurses' Health Study and the Physicians' Health Study. *Mol Carcinog* 44:21–30. doi:10.1002/mc.20112
- Tsuge H, Ago H, Aoki M, Furuno M, Noma M, Miyano M, Minami M, Izumi T, Shimizu T (1994) Crystallization and preliminary X-ray crystallographic studies of recombinant human leukotriene A4 hydrolase complexed with bestatin. *J Mol Biol* 238:854–856. doi:10.1006/jmbi.1994.1341
- Tzeng HF, Laughlin LT, Armstrong RN (1998) Semifunctional site-specific mutants affecting the hydrolytic half-reaction of microsomal epoxide hydrolase. *Biochemistry* 37:2905–2911. doi:10.1021/bi9727388
- van Bladeren PJ, Sayer JM, Ryan DE, Thomas PE, Levin W, Jerina DM (1985) Differential stereoselectivity of cytochromes P-450b and P-450c in the formation of naphthalene and anthracene 1, 2-oxides. The role of epoxide hydrolase in determining the enantiomer composition of the 1, 2-dihydrodiols formed. *J Biol Chem* 260:10226–10235
- van der Werf MJ, Overkamp KM, de Bont JA (1998) Limonene-1, 2-epoxide hydrolase from *Rhodococcus erythropolis* DCL14 belongs to a novel class of epoxide hydrolases. *J Bacteriol* 180:5052–5057
- van Loo B, Kingma J, Arand M, Wubbolts MG, Janssen DB (2006) Diversity and biocatalytic potential of epoxide hydrolases identified by genome analysis. *Appl Environ Microbiol* 72:2905–2917. doi:10.1128/AEM.72.4.2905-2917.2006
- Vejux A, Kahn E, Menetrier F, Montange T, Lherminier J, Riedinger JM, Lizard G (2007) Cytotoxic oxysterols induce caspase-independent myelin figure formation and caspase-dependent polar lipid accumulation. *Histochem Cell Biol* 127:609–624. doi:10.1007/s00418-006-0268-0
- von Dippe P, Zhu QS, Levy D (2003) Cell surface expression and bile acid transport function of one topological form of m-epoxide hydrolase. *Biochem Biophys Res Commun* 309:804–809. doi:10.1016/j.bbrc.2003.08.074

- Wang W, Kim R, Jancarik J, Yokota H, Kim SH (2001) Crystal structure of phosphoserine phosphatase from *Methanococcus jannaschii*, a hyperthermophile, at 1.8 Å resolution. *Structure* 9:65–71. doi:10.1016/S0969-2126(00)00558-X
- Wang W, Cho HS, Kim R, Jancarik J, Yokota H, Nguyen HH, Grigoriev IV, Wemmer DE, Kim SH (2002) Structural characterization of the reaction pathway in phosphoserine phosphatase: crystallographic “snapshots” of intermediate states. *J Mol Biol* 319:421–431. doi:10.1016/S0022-2836(02)00324-8
- Watabe T, Kanai M, Isobe M, Ozawa N (1981) The hepatic microsomal biotransformation of delta 5-steroids to 5 alpha, 6 beta-glycols via alpha- and beta-epoxides. *J Biol Chem* 256:2900–2907
- Watabe T, Ozawa N, Ishii H, Chiba K, Hiratsuka A (1986) Hepatic microsomal cholesterol epoxide hydrolase: selective inhibition by detergents and separation from xenobiotic epoxide hydrolase. *Biochem Biophys Res Commun* 140:632–637. doi:10.1016/0006-291X(86)90778-3
- Wickliffe JK, Herring SM, Hallberg LM, Galbert LA, Masters OEIII, Ammenheuser MM, Xie J, Friedberg EC, Lloyd RS, Abdel-Rahman SZ, Ward JB Jr (2007) Detoxification of olefinic epoxides and nucleotide excision repair of epoxide-mediated DNA damage: Insights from animal models examining human sensitivity to 1, 3-butadiene. *Chem Biol Interact* 166:226–231. doi:10.1016/j.cbi.2006.04.017
- Wild CP, Yin F, Turner PC, Chemin I, Chapot B, Mendy M, Whittle H, Kirk GD, Hall AJ (2000) Environmental and genetic determinants of aflatoxin-albumin adducts in the Gambia. *Int J Cancer* 86:1–7. doi:10.1002/(SICI)1097-0215(20000401)86:1<1::AID-IJC1>3.0.CO;2-I
- Wilson AM, Sisk RM, O'Brien NM (1997) Modulation of cholestane-3 beta, 5 alpha, 6 beta-triol toxicity by butylated hydroxytoluene, alpha-tocopherol and beta-carotene in newborn rat kidney cells in vitro. *Br J Nutr* 78:479–492. doi:10.1079/BJN19970165
- Yamashita S, Tsujino Y, Moriguchi K, Tatematsu M, Ushijima T (2006) Chemical genomic screening for methylation-silenced genes in gastric cancer cell lines using 5-aza-2'-deoxycytidine treatment and oligonucleotide microarray. *Cancer Sci* 97:64–71. doi:10.1111/j.1349-7006.2006.00136.x
- Yu Z, Schneider C, Boeglin WE, Brash AR (2007) Epidermal lipoxygenase products of the hepoxilin pathway selectively activate the nuclear receptor PPARalpha. *Lipids* 42:491–497. doi:10.1007/s11745-007-3054-4
- Zeldin DC, Kobayashi J, Falck JR, Winder BS, Hammock BD, Snapper JR, Capdevila JH (1993) Regio- and enantiofacial selectivity of epoxyeicosatrienoic acid hydration by cytosolic epoxide hydrolase. *J Biol Chem* 268:6402–6407
- Zeldin DC, Moomaw CR, Jesse N, Tomer KB, Beetham J, Hammock BD, Wu S (1996) Biochemical characterization of the human liver cytochrome P450 arachidonic acid epoxygenase pathway. *Arch Biochem Biophys* 330:87–96. doi:10.1006/abbi.1996.0229
- Zhang W, Koerner IP, Noppens R, Grafe M, Tsai HJ, Morisseau C, Luria A, Hammock BD, Falck JR, Alkayed NJ (2007) Soluble epoxide hydrolase: a novel therapeutic target in stroke. *J Cereb Blood Flow Metab* 27:1931–1940. doi:10.1038/sj.jcbfm.9600494
- Zhang L, Ding H, Yan J, Hui R, Wang W, Kissling GE, Zeldin DC, Wang DW (2008a) Genetic variation in cytochrome P450 2J2 and soluble epoxide hydrolase and risk of ischemic stroke in a Chinese population. *Pharmacogenet Genomics* 18:45–51. doi:10.1097/FPC.0b013e3282f313e8
- Zhang W, Otsuka T, Sugo N, Ardeshiri A, Alhadid YK, Iliff JJ, DeBarber AE, Koop DR, Alkayed NJ (2008b) Soluble epoxide hydrolase gene deletion is protective against experimental cerebral ischemia. *Stroke* 39:2073–2078. doi:10.1161/STROKEAHA.107.508325
- Zhao X, Yamamoto T, Newman JW, Kim IH, Watanabe T, Hammock BD, Stewart J, Pollock JS, Pollock DM, Imig JD (2004) Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. *J Am Soc Nephrol* 15:1244–1253
- Zhou GX, Ding XL, Huang JF, Zhang H, Wu SB (2007) Suppression of 5-lipoxygenase gene is involved in triptolide-induced apoptosis in pancreatic tumor cell lines. *Biochim Biophys Acta* 1770:1021–1027
- Zhu QS, Qian B, Levy D (2004) Regulation of human microsomal epoxide hydrolase gene (EPHX1) expression by the transcription factor GATA-4. *Biochim Biophys Acta* 1676:251–260
- Zou J, Hallberg BM, Bergfors T, Oesch F, Arand M, Mowbray SL, Jones TA (2000) Structure of *Aspergillus niger* epoxide hydrolase at 1.8 Å resolution: implications for the structure and function of the mammalian microsomal class of epoxide hydrolases. *Structure* 8:111–122. doi:10.1016/S0969-2126(00)00087-3
- Zusterzeel PL, Peters WH, Visser W, Hermsen KJ, Roelofs HM, Steegers EA (2001) A polymorphism in the gene for microsomal epoxide hydrolase is associated with pre-eclampsia. *J Med Genet* 38:234–237. doi:10.1136/jmg.38.4.234